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Cardiovascular disease is one of the leading causes of morbidity and mortality in 
industrialized countries [1,2]. Mortality data for 2007 show that cardiovascular 
disease accounted for 33.6% of all deaths in the United States (US) and coronary 
heart disease (CHD) caused approximately 1 of every 6 deaths [3]. Numbers are 
similar in the Netherlands where cardiovascular disease accounted for 
approximately 30% of total deaths in 2009 [4]. The prevalence of CHD in the 
Netherlands in 2009 was estimated to be 5.0% for men and 2.9% for women. The 
prevalence increased with age with a prevalence of 0.01% for men aged below 30 
and 34.3% for men older than 85 years. For women the prevalence increased from 
0.01% to 23.1% [5]. CHD refers to an abnormality of the arteries that supply blood 
and oxygen to the heart, generally caused by atherosclerosis. Blockages in the 
coronary arteries can lead to an acute myocardial infarction (MI).  
 
In addition to traditional risk factors for CHD, research has demonstrated an 
association between psychological factors, such as stress, and CHD [6,7]. Affective 
disorders are clinical expressions of stress and can be diagnosed accurately [8]. 
According to the World Health Organization, cardiovascular disease and 
depression are the most important sources of worldwide disease burden over the 
period 2002-2030, especially in high income countries [9]. The 12-month 
prevalence of depressive and anxiety disorder is respectively 5.2% and 10.1% in 
the Netherlands for persons between the ages of 18 and 64 years old [10]. In 
patients with CHD the prevalence of these disorders is 1.5 to 2 times higher and it 
is estimated that every year 35.000 to 80.000 CHD patients suffer from depressive 
disorder and 70.000 to 90.000 from anxiety disorder in the Netherlands [11]. 
 
The relationship between anxiety and CHD 
 
Generally, anxiety refers to an emotional status, characterized by feelings of 
apprehension (worries and concerns) and tension as well as increased activity of 
the autonomic nervous system in response to a perceived threat. It occurs along a 
spectrum form normal to pathologic states. Anxiety disorders, as listed in the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), include among 
others generalized anxiety disorder (GAD), panic disorder, agoraphobia, post-
traumatic stress disorder, specific phobia, and social phobia, and represent severe 




characterized by fear and a sense of uncertainty, elevated anxiety levels are very 
common in MI patients, with an in-hospital incidence of 30-40% [13,14] and 
persist over the long term in about 50% of anxious patients [15,16]. 
Few studies have assessed the relationship of anxiety with cardiac prognosis. Some 
studies suggested that anxiety plays a role in the development and prognosis of 
CHD [15,17-19] (potentially as a result of sympathetic-parasympathetic imbalance 
and unfavorable effects on the hypothalamic-pituitary-adrenal axis) but there are 
also studies that did not find evidence for anxiety as an etiologic or prognostic risk 
factor [20,21]. It has also been suggested that anxiety might have a positive impact 
on patient prognosis as a result of an increased awareness of cardiovascular 
symptoms and an increased motivation to control cardiovascular risk factors [14]. 
Anxious patients seem to receive more coronary angiographies and are therefore 
potentially more likely to be treated with percutaneous coronary intervention, 
which could subsequently lead to better cardiac outcomes [14]. However, studies 
investigating this subject have been sparse. In addition, studies assessing health 
behaviors of anxious MI patients did not find a positive effect of anxiety, besides a 
better adherence to carrying medical supplies [22], and found that anxious patients 
are less likely to adhere to risk reducing recommendations, namely adherence to 
exercise, reducing stress, increasing socialization and smoking cessation [14,22]. 
Therefore, it might be that it is anxiety in combination with nonprotective patient 
behavior that leads to a worse prognosis, possibly due to an avoidant coping 
strategy. 
Although anxiety and depression have distinctive features [23], they often co-occur 
in MI patients [24]. Since anxiety and depression are closely associated, it is 
unclear whether anxiety has incremental value independent from depression. 
Another gap in the current literature is that almost all studies looked at symptoms 
of anxiety and did not assess anxiety disorders. Anxiety questionnaires can be used 
as screening tools [19,25] but are not sufficient to diagnose anxiety disorder. To 
our knowledge, only two studies have examined the association between anxiety 
disorder (as assessed with a diagnostic interview) and adverse cardiac prognosis 
[19,26]. Since questionnaires are often inadequate in distinguishing anxiety from 
depression [19,27] it is important to assess the relationship between anxiety 
disorders and cardiac prognosis.  
Because it is unclear whether anxiety is related to the development and progression 




any association between anxiety and CHD is independent from traditional 
cardiovascular risk factors and depression. 
The relationship between depression and CHD  
Depression is a heterogeneous syndrome characterized by depressed mood and/or 
loss of interest in combination with a number of associated symptoms [28]. The 
prevalence of depression is high in patients with CHD. For example, following 
acute MI, approximately 20% of patients suffer from major depressive disorder 
[29]. During the last decades, substantial research has focused on the association 
between depression and CHD. Several meta-analyses imply that depression is a 
risk factor for the development of CHD in the general population [30,31] and is 
associated with adverse prognosis in patients with CHD independent of 
demographic and clinical risk factors [32-35]. Despite the considerable amount of 
research focusing on the relationship between depression and CHD, there are still 
numerous unresolved issues [36].  
 
The confounding role of cardiovascular disease severity 
There are methodological issues in existing prognostic studies, including 
incomplete adjustment for cardiovascular disease severity [32,35]. Depression has 
been found to be significantly related to the severity of left ventricular dysfunction 
in MI patients [37], though another recent study showed no relationship between 
depression and a comprehensive index of clinical mortality predictors [38]. In 
patients with stable CHD, depression was also not related to measures of disease 
severity (systolic dysfunction, diastolic dysfunction, exercise-induced ischemia, 
and cardiac wall motion abnormalities) [39]. However, the authors of one of the 
above-mentioned meta-analyses, noted that adjustment for left ventricular ejection 
fraction (LVEF) in 8 studies reduced risk estimates of depression for cardiac 
outcomes by almost 50%, but only 8 out of 34 studies in their review adjusted for 
LVEF [35]. Therefore, the relationship between depression and adverse prognosis 
might be influenced by inadequate adjustment for confounding due to 
cardiovascular disease severity but this topic remains controversial and more 
research is warranted.  
Effects of antidepressant treatment trials 
Randomized controlled trials focusing on the effects of antidepressant treatment 




symptoms [40,41]. However, further analyses of these studies revealed that some 
subtypes of patients might have benefited more from the intervention, for example 
white men [42] and patients treated with selective serotonin reuptake inhibitors 
[43]. In addition, secondary analyses of these studies have shown that patients who 
did not respond to antidepressant treatment were at increased risk of adverse 
cardiac events [44,45]. Therefore, depression that does not respond to treatment 
may be associated with a particularly high risk of cardiac morbidity or mortality in 
patients with CHD [46]. 
Prognostic differences between depressive symptom clusters 
 
Two dimensions of depression are often identified in depressed patients with CHD, 
namely somatic/affective and cognitive/affective symptoms. Several studies have 
reported that somatic/affective symptoms of depression (e.g., fatigue and sleep 
problems), but not cognitive/affective symptoms (e.g., shame, guilt, and negative 
self-image), were related to disease severity and adverse cardiac prognosis 
following an MI [47-49]. In contrast, other studies found that cognitive depressive 
symptoms were related to cardiac morbidity and mortality in patients who 
underwent coronary revascularization [50,51]. It is possible that somatic depressive 
symptoms are physical manifestations of more severe heart disease [47]. Therefore, 
although studies focusing on somatic depressive symptoms and cardiac prognosis 
adjusted for measures of disease severity, there remains a possibility of underlying 
cardiac disease explaining the relationship between somatic depressive symptoms 
and cardiac prognosis.  
 
These studies indicate the need for a closer look at the relationship between 
depressive symptoms and CHD. In order to improve depressive symptoms and 
cardiac prognosis of CHD patients, it is important to assess which subtypes of 
depression are more important predictors of adverse cardiac events and to 
determine which patients do not adequately respond to antidepressant treatment. In 
addition, no studies in patients with CHD have focused on changes in cognitive and 
somatic depressive symptoms after depression treatment and their potentially 








Aims and organization of the present thesis 
 
The general aim of this thesis is to study the potential effect of anxiety and 
depression on CHD. Compared with depression, much less research has focused on 
the association of anxiety with CHD. Therefore, the first aim of this thesis is to 
broaden the attention to anxiety as a potential risk factor for the development and 
progression of CHD. Because of the unresolved issues concerning the effect of 
depression on CHD, the second aim of this thesis is to provide a deeper 
understanding of the role of depression in CHD.  
The link between anxiety and development and progression of CHD 
The first part of this thesis focuses on the relationship between anxiety and CHD. 
Since studies on the association between anxiety and CHD found contradictory 
results, it is unclear whether anxiety is a risk factor for the development and/or 
progression of CHD. Meta-analytic research can help to resolve these 
inconsistencies. Therefore, chapter 2 reports on a meta-analysis regarding the 
impact of anxiety on the development of CHD in initially healthy persons. The aim 
of this study was to investigate the association of symptoms of anxiety with 
incident CHD independent of traditional cardiovascular risk factors.  
In chapter 3 we report on a meta-analysis on the prognostic association of anxiety 
in MI patients with medical outcomes. The objective of this study was to 
investigate the association of anxiety symptoms following acute MI with mortality 
and cardiac events and to assess this association in light of available covariates.  
In chapter 4 we evaluated the association of GAD following MI with cardiac 
events and mortality using a formal psychiatric interview. We also analyzed 
whether GAD was a predictor of adverse prognosis after adjustment for depressive 
disorder. For this study, patients were included from the Depression after 
Myocardial Infarction (DepreMI) study, which was conducted in 4 hospitals in the 
Netherlands. DepreMI was a naturalistic cohort study evaluating the effects of 












The link between depressive symptom dimensions, treatment response, and CHD 
The second part of the thesis focuses on the relationship between depression and 
CHD. In Chapter 5 we assessed the differential associations of depressive 
symptom dimensions with mortality in patients with acute coronary syndrome 
(ACS). The aim of the study was to investigate the associations of 
somatic/affective and cognitive/affective depressive symptoms following ACS 
with disease severity at baseline and all-cause mortality at 12-month follow-up. 
This was a prospective study following patients admitted with MI or unstable 
angina to 12 coronary care units across South-central Ontario, Canada.  
Chapter 6 describes a secondary analysis of data from the Enhancing Recovery in 
Coronary Heart Disease (ENRICHD) trial. ENRICHD was a randomized 
controlled trial to determine whether treatment of depression and low social 
support could improve medical outcome following MI. In this study 2481 MI 
patients with depressive disorder or low social support were recruited from 8 
clinical sites in the US and were randomized to either cognitive behavior therapy 
(CBT) combined with concurrent antidepressant medication when necessary or 
care as usual. The intervention did not increase event-free survival in the primary 
analysis [40]. In this secondary analysis we assessed whether somatic and cognitive 
depressive symptoms improved after CBT in the depressed patients and whether 
treatment-related changes in somatic or cognitive depressive symptoms following 
acute MI were related to event-free survival.  
Chapter 7 assesses the possibility that obstructive sleep apnea hypopnea (OSAH) 
causes resistance to antidepressant medication in depressed patients with CHD. 
OSAH is a chronic, sleep-related breathing disorder characterized by recurrent, 
complete (apnea) or partial (hypopnea) blockage of the upper airway. OSAH is a 
significant risk factor for acute MI and sudden cardiac death in patients with CHD 
[52,53] and is linked to treatment-resistant depression in depressed psychiatric 
Outline of part 1: Anxiety and coronary heart disease 
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patients [54]. This study tested the hypothesis that the presence of OSAH is 
associated with a poor response to antidepressant treatment in patients with CHD. 
If undiagnosed OSAH is one of the causes of poor response to antidepressants, this 
could help to explain the adverse cardiovascular outcomes that have been 
associated with treatment-resistant depression in CHD patients. This question was 
examined using data collected for a randomized, double blinded, placebo-
controlled clinical trial of omega-3 augmentation of sertraline for depression in 
patients with CHD. Patients were recruited from cardiology practices in St. Louis, 
MO, US and from cardiac diagnostic laboratories affiliated with Washington 











Summary and general discussion 
 
In chapter 8 the main findings of the thesis will be summarized. Also, clinical 
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Anxiety and risk of incident coronary 
heart disease: a meta-analysis 
Roest AM, Martens EJ, de Jonge P, Denollet J 





Objectives: Our objective was to assess the association between anxiety and risk 
of coronary heart disease (CHD). Background: In contrast to other negative 
emotions, such as depression, less research has focused on the association of 
anxiety with incident CHD. Methods: A meta-analysis of references derived from 
PubMed, EMBASE and PsychINFO (1980- May 2009) was performed without 
language restrictions. Endpoints were cardiac death, myocardial infarction (MI) 
and cardiac events. The authors selected prospective studies of (non-psychiatric) 
cohorts of initially healthy persons in which anxiety was assessed at baseline. 
Results: Twenty studies reporting on incident CHD enclosed 249.846 persons with 
a mean follow-up period of 11.2 years. Anxious persons were at risk of CHD 
(hazard ratio (HR) random: 1.26; 95% confidence interval (CI): 1.15-1.38; 
p<0.0001) and cardiac death (HR: 1.48; 95% CI: 1.14-1.92; p=0.003), independent 
of demographic variables, biological risk factors and health behaviors. There was a 
nonsignificant trend for an association between anxiety and non-fatal MI (HR: 1.43; 
95% CI: 0.85-2.40; p=0.180). Subgroup analyses did not show any significant 
differences regarding study characteristics, with significant associations for 
different types of anxiety, short and long-term follow-up and both men and women. 
Conclusions: Anxiety appeared to be an independent risk factor for incident CHD 
and cardiac mortality. Future research should examine the association between 
anxiety and CHD with valid and reliable anxiety measures and focus on the 
mechanisms through which anxiety may affect CHD.  




Research has demonstrated an association between psychological factors such as 
stress, and both the development of coronary heart disease (CHD) and CHD 
outcomes [1,2]. Most studies have focused on the role of depression, with several 
meta-analyses indicating that depression is an independent risk factor for the 
development of CHD in the general population [3], as well as a prognostic risk 
factor in CHD patients [4]. While evidence suggests that anxiety also has an 
adverse impact on prognosis in CHD patients independent of depression [5-8], the 
role of anxiety as an etiological risk factor is less clear. While several studies 
suggest that anxiety may contribute to the development of CHD in initially healthy 
individuals [9] and found an effect on cardiac death [10-12] or incident myocardial 
infarction (MI) [13,14], others have found no association [15,16].  
Meta-analytic research may help to resolve these inconsistencies but, to our 
knowledge, no recent meta-analysis has yet been conducted on the association 
between anxiety and incident heart disease. The present meta-analysis therefore 
focuses on the impact of anxiety on the development of CHD in initially healthy 
persons. The first objective of this study was to investigate the association of 
anxiety with incident CHD independent of traditional cardiovascular risk factors. 
The second objective was to examine whether the associations between anxiety and 
incident CHD were different for MI versus cardiac mortality as outcomes. 
Methods 
The aim was to assess the association between a comprehensive set of common 
anxiety constructs (including anxiety, panic, phobia, post-traumatic stress, and 
worry) and incident CHD. We identified all studies available by May 2009, on the 
development of CHD in anxious versus non-anxious persons. Methods for 
systematic identification, appraisal, synthesis and statistical aggregation of 
information, and reporting of results were chosen according to predetermined 
methods [17,18].  
Literature search 
The electronic databases PubMed, EMBASE and PsychINFO (1980- May 2009) 
were searched using the following terms: “(community or cohort or healthy 
persons or risk) and (anxiety or post traumatic stress disorder or tension or anxiety 




or worry) and (mortality or coronary mortality or myocardial infarction or coronary 
heart disease or sudden cardiac death)”. There were no language restrictions and 
both published and unpublished data were included. In addition, reference lists of 
included studies and review articles were checked to identify additional studies 
meeting selection criteria. 
Selection 
Two independent raters (A.R. and J.D.) identified studies meeting the following 
pre specified inclusion criteria:  
1. Studies were prospective in nature, following a (non-psychiatric) cohort of 
initially healthy persons over time. 
2. At baseline, studies had to include at least one self-report or interview-based 
assessment of anxiety symptoms or anxiety disorder; e.g., post traumatic stress 
disorder, tension, worry, phobic anxiety, panic, or generalized anxiety disorder.  
3. Endpoints included cardiac mortality or MI. 
Studies focusing explicitly on older persons (over 75 years old) were excluded. 
During the selection procedure, in case of disagreement between the two raters, the 
four investigators discussed the difference of opinion until consensus was reached. 
When study samples included healthy persons combined with a small number of 
heart disease patients, these studies were included when the original study adjusted 
for the presence of medical conditions [15,16,19-22]. Regarding multiple reports 
on the same dataset, only one paper was included based on the anxiety measure, 
study sample, endpoint, and follow-up period, preferring (in order of importance) 
general anxiety measured with a reliable and valid measure, multiple cardiac 
endpoints (e.g., cardiac mortality and MI), larger sample sizes, and longer follow-
up periods. Regarding the different papers reporting on the Normative Aging Study, 
the study of Kubzansky et al. [23] was included because this study reported on 
general anxiety as measured with the Minnesota Multiphasic Personality Inventory 
(MMPI) and on non-fatal MI and cardiac mortality. We included both studies of 
Haines et al. [10,24], as they represented different outcomes. We retrieved the 
association between phobic anxiety and cardiac mortality from the later study 
(given the longer follow-up period) [24], and the association between phobic 
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anxiety and MI from the earlier study [10]. If necessary, the corresponding authors 
of the eligible studies were asked to provide additional information.    
Information on sample size and characteristics (e.g. did the researchers include 
specific in-/exclusion criteria such as gender), anxiety assessment, endpoints, 
participation rate, percentage lost to follow-up, follow-up duration, bivariate and 
fully-adjusted relative risks and 95% confidence intervals (CI), and variables used 
in multivariable analysis was abstracted and evaluated. We did not weigh the 
contribution of each study to the meta-analysis on the basis of quality scoring for 
there are no validated measures of quality for observational studies and the use of 
subjective rating scales may lead to bias [25]. 
Endpoints 
We examined the association between anxiety and incident CHD. If a study 
reported on MI and cardiac mortality separately, we included cardiac mortality as 
endpoint [23,26]. Concerning the papers of Haines et al., we included their study 
reporting on cardiac mortality [24]. We focused on hard medical endpoints and, if 
possible, kept angina out of our analysis [23,27] because anxiety may be associated 
with the report of symptoms of chest pain without reflecting underlying CHD [27]. 
One included study reported on a broader endpoint, namely cardiovascular events 
(including cardiac death and non-fatal MI) [19]. We also examined the associations 
between anxiety and non-fatal MI and cardiac mortality (including sudden cardiac 
death and other cardiac death) separately.  
Quantitative data synthesis 
Data from all studies were pooled. We combined hazard ratios, relative risks and 
odds ratios from multivariable analyses. For one paper we had to recalculate the CI 
[22] because the log values for lower and upper limits were not symmetric. We 
suspected a relatively large heterogeneity in results given that the included studies 
differed in anxiety types, anxiety measures, and sample characteristics (e.g., 
gender). We therefore used the Random Effects Method to generate a summary 
estimate of effect estimates and tested the amount of heterogeneity with the Q test 
of homogeneity and the I² test, which indicates the proportion of total variance 
explained by heterogeneity.   
In one study the relative risk of anxiety predicting CHD was expressed relative to a 




and CI, based on the assumption of normal distribution, assuming that 20% of the 
sample experienced increased anxiety (mean anxiety prevalence of other included 
studies).  
If a study included various scales of the Crown Crisp index, e.g. Haines et al. 
[10,24], the phobic anxiety scale was selected because it was most representative of 
other studies using the Crown Crisp Index [11,26]. If the association between 
anxiety and CHD was assessed separately for men and women, we included that 
study twice with sample sizes according to the number of men and women in the 
study [22,28]. In the studies from Eaker et al. [28,29], the tension scale was used 
because it reflects psychological symptoms of anxiety whereas the anxiety scale 
mainly reflects physiological arousal [28] that may be confounded by underlying 
cardiac disease.  
We conducted a subgroup comparison between studies including all persons versus 
studies focusing on the contrast between high versus low anxiety subgroups.  
If study outcomes were heterogeneous based on the I2 test/Q test, the possible 
effects of anxiety type, follow-up period and study sample (healthy persons versus 
healthy and heart disease patients and men versus women) were studied. 
Differences in effect estimates between the subgroups were assessed by comparing 
the pooled effect estimates using chi-squared analysis, comparing logarithms of 
these estimates. In order to evaluate the presence of publication bias, a funnel plot 
was constructed by plotting the effect measure against the inverse of its standard 
error. We used Egger’s test of the intercept, the classic fail-safe N and Duval and 
Tweedie’s Trim and Fill test to estimate the severity of publication bias. All 
analyses were performed with the program Comprehensive Meta-Analysis version 
2. 
Additional information by personal communication 
The author of one included study was contacted for further information and 
supplied us with the multivariable hazard ratio (HR) of anxiety predicting 
cardiovascular events [19]. 
Results 
A flow diagram of the literature search is shown in Figure 1. The agreement rates 
(Cohen’s kappa) for the 2 steps in the selection procedure were 0.81 and 0.94 
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respectively, indicating very good consistency of judgment by raters [30]. Twenty-
one studies, published between 1987 and 2009, met selection criteria of which the 
characteristics are shown in tables 1 and 2. Of these studies, 20 reported on 
incident CHD, 9 on cardiac mortality and 5 on non-fatal MI. 
Figure 1: Flow-chart of literature search 
a Both reports of Haines et al. [10,24] were included; one with cardiac death [24] and one with non-fatal MI [10] as 
endpoint. CHD= coronary heart disease; MI= myocardial infarction. 
 
































































































Phillips, 2009 (21) 4256 38 100 USA, 1986  69 0 DIS Generalized anxiety 
disorder 
14.6 Cardiac mortality 
Kubzanksy, 2009 
(38)  
1059 44 0 USA, 1982 NA 23.6 NIMH DIS PTSD symptoms  14.0 Cardiac events a 
Einvik, 2009 (19) 433  NA 100 Norway, 1997 72 0 HADS-A General  3.0 Cardiovascular events b 
Denollet, 2008 (32) 5073 50 0 The Netherlands, 
1994 
83 0  EDS 
Anxiety subscale 
General  10.0 Cardiac mortality 
Mykletun, 2007 (15)  61349 48 NA Norway, 1995 66 NA HADS-A General  4.4  Cardiac mortality 
Smoller, 2007 (20) 3369 66 
 
0 USA, 1997 NA 0.03 Questionnaire based on 
DSM-IV 
Panic attacks 5.3  Cardiac events c 
Gafarov, 2007 (31) 2149 NA 100 Russia, 1984 NA NA STAI General 20.0 MI 
Kubzansky, 2006 
(23)  
1306 61  
 
100 USA, 1986 82.4 NA MMPI-2 
Anxiety subscale 
General  10.9 Non-fatal MI and  cardiac 
mortality 
Thurston, 2006 (40) 6265 NA 46 USA, 1971 70 0 GWB-A General  15.1 Cardiac events d 
Boyle, 2006 (39)  2105 47 100 USA, 1985 NA 3.0 MMPI-2 General  15.0 IHD 
Albert, 2005 (26) 72359 54 
 
0 USA, 1988  NA 2.0 CCI 
Phobia index 
Phobic 12.0 Non-fatal MI and cardiac 
mortality 
Eaker, 2005 (28) 3682 49 48 USA, 1984  NA <5 Tension and Symptoms of 
Anxiety Scales 
General  10.0 Cardiac events e 
Nicholson, 2005 
(27)  
5449 NA 100 UK, 1985 74 NA GHQ-30 Anxiety subscale General  6.8 Cardiac events c 
Ringbäck Weitoft, 
2005 (22)  
34511 43 50 Sweden, 1980 79-
86 
NA Single question General  5.0  IHD 




CCI= Crown-Crisp Index; DIS= Diagnostic Interview Schedule; DSM= Diagnostic Statistical Manual; EDS= Edinburgh Depression Scale; GHQ= General Health 
Questionnaire; GWB-A= General Well-Being Schedule anxiety subscale; HADS-A= Hospital Anxiety and Depression Scale, anxiety subscale; IHD= ischemic heart disease; 
MI= myocardial infarction; MMPI= Minnesota Multiphasic Personality Inventory; NA= not available; PTSD= Post traumatic stress disorder; STAI= Stait Trait Anxiety Index.  
 
a = angina pectoris, non-fatal MI, fatal MI and other cardiac death 
b = cardiac death, non-fatal MI, percuataneous coronary intervention, CABG, cerebral stroke, surgery on abdominal aortic aneurysm and revascularization in peripheral arterial 
disease 
c = non-fatal MI and cardiac death 
d = MI, other acute and subacute ischemic heart disease, other forms of chronic ischemic heart disease 
 e = non-fatal MI, coronary insufficiency and cardiac death 
Haines, 2001 (24) 1408 NA 100 UK, 1972 80 NA CCI Phobia index Phobic  20.9 Cardiac mortality 
Kawachi, 1994 (11)  33999 NA 100 USA, 1986 NA 4.0 CCI Phobia index Phobic 2.0 Non-fatal MI and cardiac 
mortality 
Vogt, 1994 (41) 2573 NA 46 USA, 1970 92 0 Bradburn Worries Index Worry 15.0 IHD 
Eaker, 1992 (29) 749 NA 0 USA, 1965  NA NA Tension and Symptoms of 
Anxiety Scales 
General 20.0 Cardiac events  c 
Rosengren, 1991 
(33) 
6935 NA 100 Sweden, 1970 76 NA Single question General 11.8 Cardiac events c  
Haines, 1987 (10) 1342 NA 100 UK, 1972 80 2.8 CCI Phobia index Phobic  6.7  Non-fatal MI 

















































Phillips, 2009 (21)  Age 2.89 (1.59-5.23) a Age, place of service, ethnicity, marital status, smoking habit, alcohol 
consumption, IQ at enlistment, household income in midlife, BMI, total 
cholesterol, SBP, blood glucose, and somatic illness. 
1.84 (0.98-3.45) 
Kubzanksy, 2009 (38) Age 3.21 (1.29-7.98) a Age, race/ethnicity, smoking status, history of high blood pressure, 
history of diabetes, alcohol use, education, income.  
3.46 (1.35-8.90) a 
Einvik, 2009 (19) - 3.17 (1.28-7.82) a Age, previous cardiovascular disease, current smoking, level of serum 
glucose, diabetes, SBP, LDL-cholesterol, alcohol use, BMI, treatment 
modality.  
3.23 (1.26-8.27) b 
Denollet, 2008 (32) Age 2.74 (1.15-6.49) a Age, education, living alone, hormone intake, smoking, alcohol, physical 
activity, BMI, hypertension, diabetes, depressive symptoms. 
2.77 (1.17-6.58) a 
Mykletun, 2007 (15)  Age and gender 1.10 (0.84-1.43) Age, gender, somatic symptoms/diagnoses, physical impairment, health-
related behavior (smoking, alcohol problems, physical activity) 
educational level and SES, physical measurement (BMI, DBP, total 
cholesterol level). 
0.89 (0.67-1.16) 
Smoller, 2007 (20) Age, race, income 1.92 (1.20-3.07) a Age, race, income, BMI, alcohol, hormone use, high cholesterol level 
requiring medication, history of diabetes mellitus treatment, smoking, 
depression, history of atrial fibrillation, hypertension status, moderate to 
strenuous activity for longer than 20 minutes 3 or more times a week, and 
history of MI, CABG, PTCA, or stroke. 
4.20 (1.76-9.99) a 
 
Gafarov, 2007 (31) - 2.70 (1.27-5.71) a - 2.70 (1.27-5.71) a 
II 
 
Kubzansky, 2006 (23)  Age 2.11 (0.8-5.6) Age, BMI, smoking status, SBP and DBP, serum cholesterol, family 
history of CHD, alcohol use, education. 
2.11 (0.8-5.8) 
Thurston, 2006 (40) Age and gender 1.56 (1.31-1.86) a Age, gender, marital status, race/ethnicity, smoking status, aerobic 
exercise, alcohol use, SBP, DBP, BMI, cholesterol, hypertension, diabetes 
status. 
1.38 (1.15-1.66) a 
Boyle, 2006 (39) Age 1.18 (1.08-1.29) a Age, total cholesterol, smoking status, hypertensive status, diabetes status, 
high density lipoprotein and BMI. 
1.15 (1.05-1.25) a 
Albert, 2005 (26) Age 1.55 (1.16-2.08) a Age, smoking status, BMI, alcohol intake, menopausal status and 
hormone use, parental history of MI, physical activity, aspirin use, valium 
use, history of hypertension, hypercholesterolemia and diabetes.  
1.18 (0.88-1.58) 
Eaker, 2005 (28) 
 men 
- NA Age, SBP, BMI, current cigarette smoking, diabetes, and total 
cholesterol/HDL cholesterol. 
1.04 (1.01-1.08) a  
Eaker, 2005 (28)  
women 
- NA Age, SBP, BMI, current cigarette smoking, diabetes, and total 
cholesterol/HDL cholesterol. 
1.00 (0.95-1.05) c  
Nicholson, 2005 (27) Age 1.28 (0.76-2.16) Age 1.28 (0.76-2.16) 
Ringbäck Weitoft, 2005 (22)  
men Age 1,82 (1.35-2.45)
 a Age, smoking, longstanding illness, education. 1.49 (1.14-1.94) a 
Ringbäck Weitoft, 2005 (22)  
women Age 1.28 (0.94-1.74) Age, smoking, longstanding illness, education. 1.04 (0.75-1.45) 
Yasuda, 2002 (16) - NA Age, gender, chronic conditions under treatment, regular physical activity, 
and availability of close or casual neighbors. 
1.84 (0.76-4.42) 
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Haines, 2001 (24) - NA Age, smoking, BMI, fibrinogen, factor VII, SBP, cholesterol, social class. 1.29 (0.71-2.34) 
Kawachi, 1994 (11) Age 1.40 (0.83-2.37) Age, smoking, alcohol, BMI, history of hypertension, diabetes mellitus, 
hypercholesterolemia, parental history of MI before the age of 60 years, 
physical activity. 
1.24 (0.73-2.11) 
Vogt, 1994 (41) - 2.34 (1.72-3.20) a Age, gender, self-reported health status, self-reported social class, 
cigarette smoking status, duration of health plan membership.  
1.18 (0.85-1.63) 
Eaker, 1992 (29) NA NA Age, SBP, ratio of the serum total cholesterol to high-density lipoprotein 
cholesterol, diabetes, cigarette smoking and BMI. 
2.9 (1.3-6.8) a 
Rosengren, 1991 (33) - 1.6 (1.3-2.0) a Age, SBP, serum cholesterol, smoking, BMI, diabetes, family history of 
MI, occupational class, marital state, leisure time physical activity, 
registration for alcohol abuse.  
1.5 (1.2-1.9) a 
Haines, 1987 (10) - NA Age, smoking habit, social class, shift (night or day), SBP, fibrinogen, 
cholesterol, factor VII activity. 
1.26 (0.62-2.54) 
 
BMI= body mass index; CABG= coronary artery bypass graft; CHD= coronary heart disease; DBP= diastolic blood pressure; MI= myocardial infarction; NA= not available; 
PTCA= percutaneous transluminal coronary angioplasty; SBP= systolic blood pressure; SES= socioeconomic status. 
 
a = Statistically significant 
b = HR received from author 





Twenty studies that reported on incident CHD enclosed 249,846 persons. Mean 
follow-up period was 11.2 years, with follow-up periods ranging from 2.0 to 20.9 
years. The mean age at baseline assessment ranged from 38 to 72 years. Eleven 
analyses reported on males, 7 on females and 4 on a combined sample of males and 
females. Fourteen analyses (70%) showed a statistically significant univariable 
association between anxiety and CHD and 10 (50%) were significant in 
multivariable analyses (table 2). 
The pooled HR for incident CHD (favoring cardiac death in case of multiple 
endpoints) was 1.26 (95% CI: 1.15-1.38; p<0.0001) when pooling multivariable 
and bivariate HRs, in case no multivariable HR was reported in the original study 
[27,33] (Figure 2). 
 
Figure 2: Anxiety and risk of incident coronary heart disease 
 
Forest plot of individual studies investigating the association between anxiety and incident coronary heart disease 
(CHD). CI= confidence interval.  
 
Study name Statistics for each study Hazard ratio and 95% CI
Hazard Lower Upper 
ratio limit limit Z-Value p-Value
Philips, 2009 1,840 0,981 3,452 1,899 0,058
Kubzanksy, 2009 3,460 1,348 8,884 2,580 0,010
Einvik, 2009 3,230 1,261 8,275 2,443 0,015
Denollet, 2008 2,770 1,168 6,569 2,313 0,021
Mykletun, 2007 0,890 0,676 1,171 -0,832 0,405
Smoller, 2007 4,200 1,763 10,006 3,240 0,001
Gafarov, 2007 2,700 1,273 5,725 2,590 0,010
Kubzansky, 2006 2,110 0,784 5,681 1,478 0,140
Thurston, 2006 1,380 1,149 1,658 3,440 0,001
Boyle, 2006 1,150 1,054 1,255 3,142 0,002
Albert, 2005 1,180 0,881 1,581 1,109 0,268
Eaker, 2005 men 1,040 1,006 1,075 2,320 0,020
Eaker, 2005 women 0,998 0,951 1,047 -0,082 0,935
Nicholson, 2005 1,280 0,759 2,158 0,926 0,354
Weitoft, 2005 men 1,490 1,142 1,944 2,940 0,003
Weitoft, 2005 women 1,040 0,748 1,446 0,233 0,816
Yasuda, 2002 1,840 0,763 4,437 1,358 0,175
Haines, 2001 1,290 0,711 2,342 0,837 0,403
Kawachi 1994 1,240 0,729 2,108 0,794 0,427
Vogt, 1994 1,180 0,852 1,634 0,996 0,319
Eaker, 1992 2,900 1,268 6,633 2,522 0,012
Rosengren, 1991 1,500 1,192 1,887 3,459 0,001
1,260 1,149 1,382 4,915 0,000
0,1 0,2 0,5 1 2 5 10
Favours A Favours BHeterogeneity Q= 81.23; p<0.0001; I²= 74,15 
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Cardiac mortality and MI 
Nine of the 21 included studies focused on cardiac mortality as a separate endpoint. 
Five studies found a significant association between anxiety and cardiac mortality 
[11,21,26,32,33], of which 3 remained significant in multivariable analyses 
[11,32,33]. The pooled multivariable HR for cardiac mortality was 1.48 (95% CI: 
1.14-1.92; p=0.003). The heterogeneity was lower than for incident CHD (Q= 
17.61; p= 0.024; I²= 54.57). 
Five studies focused on non-fatal MI as a separate endpoint. Two studies found a 
significant association between general anxiety and MI [23,31], although one did 
not adjust for confounders [31]. The pooled HR for non-fatal MI was 1.43 (95% CI: 
0.85-2.40; p=0.180). When excluding the paper that did not adjust for confounders 
[33], the HR decreased to 1.23 (95% CI: 0.74-2.05; p=0.416). There was no 
significant difference between the impact of anxiety on cardiac death versus non-
fatal MI (p=0.91).  
Subgroup analyses 
Studies which included all persons in their analyses had a smaller pooled HR (1.19; 
95% CI: 1.07-1.33) in comparison with studies focusing on the contrast between 
high versus low anxiety subgroups (HR: 1.39; 95% CI: 1.16-1.66), but this 
difference was not statistically significant (p=0.15). There were no further 
differences for study sample, anxiety type and follow-up period. 
A funnel plot of selected studies on the primary outcome suggested the presence of 
publication bias. Egger’s test showed a significant asymmetry (p<0.0001). The 
Fail-Safe N shows that another 389 null-studies are needed in order for the p-value 
to exceed 0.05. According to the Trim and Fill test, the association between anxiety 
and CHD remains significant after imputing possible missing studies (HR: 1.16; 95% 




   Figure 3: Funnel plot of selected studies with possible missing studies imputed. 
 
 




This is the first meta-analysis focusing on the association of anxiety with the 
incidence of CHD in initially healthy individuals. The results show an association 
between anxiety and incident CHD with a 26% increase in risk. Anxiety was also 
specifically associated with cardiac mortality, with anxious persons having a 48% 
increased risk of cardiac death. There was a trend for an association between 
anxiety and incident non-fatal MI, but this association was based on only 5 studies. 
Subgroup analyses did not show any significant differences regarding study 
characteristics with significant associations for different types of anxiety, short and 
long-term follow-up and both men and women. Secondary analyses in the original 



















Funnel Plot of Standard Error by Log hazard ratio
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studies, excluding heart disease patients at baseline, did also not affect the results 
[19,20].  
Recently published studies using large databases demonstrated a significant 
association between anxiety and MI [34] and panic disorder and CHD [35,36].  
Strength of this meta-analysis is the adjustment for covariates in most of the 
individual studies that were included. Only 2 studies did not adjust for covariates 
[27,31], of which one reported a significant association between anxiety and MI 
[31]. All other studies adjusted for a variety of demographic variables, biological 
risk factors and health behaviors. After adjustment for these variables, the HRs 
decreased, but still remained significant.  
It is important to compare the strength of the association between anxiety and 
incident CHD with other psychological constructs. A recent meta-analysis showed 
that depression was associated with a 46% increased risk of cardiovascular disease 
[37], and the impact of depression on cardiac death (55% increased risk) was 
comparable to the impact of anxiety found in the present meta-analysis. Five 
studies on anxiety and CHD adjusted for depression in their analyses 
[20,23,32,38,39], and four associations remained significant [20,23,32,38]. In a 
study by Phillips et al. [21], subjects with both generalized anxiety disorder and 
major depressive disorder were at greatest risk of subsequent cardiac death, 
suggesting that anxiety and depression may also interact synergistically to affect 
CHD. Anxiety and depression have a moderate to strong correlation and it is 
possible that anxiety and depression are both part of a larger and more stable 
psychological factor influencing heart disease, like negative affectivity [42,43]. A 
recent meta-analysis focusing on the association of anger and hostility with CHD 
found a 19% increased risk, but (a) this association was no longer significant after 
adjusting for possible behavioral covariates [44] and (b) the association with CHD 
mortality was not significant [44]. This difference in anxiety and anger as potential 
predictors of cardiac death is of interest, and calls for confirmation in future 
research. 
There are several potential mechanisms that may help to explain the adverse 
association between anxiety and CHD. Anxiety has been associated with 
progression of atherosclerosis [45], decreased heart rate variability [46] and risk of 
ventricular arrhythmias [47,48]. Research supports the risk of arrhythmias 




between phobic anxiety and sudden cardiac death, but not with non-fatal MI 
[11,26]. More research is needed focusing on these possible mechanisms and the 
impact on different outcomes, particularly MI versus (sudden) cardiac death. 
Furthermore, anxiety is related to an unhealthy lifestyle in patients at risk of CHD 
[49]. In the present meta-analysis, unhealthy lifestyles (e.g. physical inactivity, 
increased body mass index and smoking) were included as covariates, but they may 
also mediate the relationship between anxiety and CHD. This might indicate that 
the association between anxiety and CHD might be larger than reported here.  
Anxiety can be treated effectively with cognitive behavior therapy and medications, 
e.g. benzodiazepines and selective serotonin reuptake inhibitors [50]. 
Unfortunately, many patients do not receive adequate treatment [50]. Besides the 
impact of anxiety on disability and decreased quality of life, clinicians should be 
aware of the risk of anxiety associated with incident heart disease. Future research 
needs to investigate whether the treatment of anxiety has a significant beneficial 
effect on the incidence or course of cardiac disease [51]. 
The results need to be considered in light of the study limitations. One important 
limitation in conducting a meta-analysis is the inevitability of combining data from 
studies that are not equally designed. Study samples were heterogeneous regarding 
age and gender and follow-up duration differed substantially across studies. Further, 
different anxiety measures were included, some of which were not extensively 
validated. As a result, the heterogeneity in our results is substantial. Also, only one 
included paper focused on an anxiety disorder, namely generalized anxiety disorder 
[21]. It is important that studies use a valid and reliable anxiety measure and more 
research is needed to the association of anxiety disorders with heart disease 
development. However, the finding of an association between anxiety and CHD 
was quite consistent across studies. Also, studies reporting on the Normative Aging 
Study showed comparable results for different anxiety types, such as post traumatic 
stress disorder [52] and worry [13], suggesting that a broad variety of anxiety 
symptoms influence incidence of CHD. Future research should focus on the 
specific aspects of anxiety that contribute to cardiac outcomes. Further, almost all 
studies were conducted in Western populations which might limit the 
generalization of the findings. Another limitation is that meta-analyses are prone to 
publication bias. We found an indication for publication bias, suggesting that the 
association between anxiety and CHD might be smaller than reported here. 
However, after adjusting for this possible bias the results still show a reliable 
association of anxiety with CHD.   
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In summary, anxiety was found to be an independent risk factor for the incidence 
of CHD and cardiac mortality in initially healthy individuals. The strength of this 
association appeared to be somewhat lower compared to the effect of depression 
but clearly higher than that of anger. Future research should examine the 
relationship between anxiety and CHD with valid and reliable anxiety measures, 
and needs to focus on the mechanisms through which anxiety may affect the 
development and onset of CHD.  
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myocardial infarction with mortality and new 
cardiac events: a meta-analysis 
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Objective: To assess the association of anxiety following myocardial infarction 
(MI) with cardiac prognosis. Methods: A meta-analysis of references derived from 
MEDLINE, EMBASE and PSYCINFO (1975- March 2009) was performed 
without language restrictions. Endpoint was cardiac outcome defined as all-cause 
mortality, cardiac mortality and cardiac events. The authors selected prospective 
studies with at least 6 months follow-up and anxiety had to be assessed within 3 
months after MI with reliable and valid instruments. Results: Twelve papers met 
selection criteria. These studies described follow-up (on average 2.6 years) of 5750 
MI patients. Anxious patients were at risk of adverse events (odds ratio (OR) fixed: 
1.36; 95% confidence interval (CI): 1.18-1.56; p<.001). Anxiety was also 
specifically associated with all-cause mortality (OR fixed: 1.47; 95% CI: 1.02-2.13; 
p=.04), cardiac mortality (OR fixed: 1.23; 95% CI: 1.03-1.47; p=.02) and new 
cardiac events (OR fixed: 1.71; 95% CI: 1.31-2.23; p<.001). Conclusions: Post-MI 
anxiety is associated with a 36% increased risk of adverse cardiac outcomes in 
bivariate analyses. Since the existing literature is quite small and contains several 
limitations, more research is needed to the association of anxiety and prognosis in 
MI patients and to assess the extent to which this association is independent of 
clinical variables, such as disease severity, and other psychological variables, 
especially depression.  




Cardiovascular disease, and in particular acute myocardial infarction (MI), is one 
of the leading causes of morbidity and mortality in industrialized countries [1,2]. 
Several meta-analyses indicate depression as a risk factor for the development of 
coronary heart disease (CHD) in the general population [3,4] and as a prognostic 
risk factor in post-MI patients [5]. In contrast, anxiety is a negative emotion on 
which much less research has focused. Although anxiety is often comorbid with 
depression, it is a distinct emotion [6]. Studies in healthy populations have 
demonstrated that anxiety is significantly related to the development of CHD [7,8]. 
In addition, anxiety is very common in MI patients, with an in-hospital incidence 
of 30-40% [9-11]. Anxiety has been found to be predictive of disability, increased 
physical symptoms, worse functional status and worse quality of life in CHD 
patients [12-14].  
The role of anxiety regarding cardiac prognosis is unclear. Several studies in CHD 
patients have shown that anxiety is related to adverse cardiac outcomes, defined as 
fatal and nonfatal cardiac events and in-hospital ischemic and arrhythmic 
complications [15-19]. However, others did not find a relationship between anxiety 
and cardiac and all-cause mortality [20-23], or even found a protective impact of 
anxiety on all-cause death, recurrent MI and revascularization [24,25]. Moreover, 
one study showed that when entering both anxiety and depression in a single 
prediction model, the effects of depression were explained away by those of 
anxiety [26], but this finding was not confirmed by other studies [27]. 
Therefore, the present paper focuses on anxiety as a predictor of medical prognosis 
after MI. To our knowledge, this is the first meta-analysis on the prognostic 
association of anxiety in heart disease patients with medical outcome. Objective of 
this study was to investigate the association of anxiety after MI with all-cause 
death, cardiac death and cardiac events and to assess this association in the light of 
available covariates.  
Methods 
Aim 
To identify all studies available by March 2009 comparing cardiac prognosis of 




synthesis, statistical aggregation and reporting of results   resembled known 
guidelines [28,29].  
Literature search 
Regarding literature search, the electronic databases MEDLINE, EMBASE and 
PSYCINFO (1975- March 2009) were searched using the following terms: 
“myocardial infarction” and “anxiety”, without language restrictions. We included 
both published and unpublished data (e.g. doctoral dissertations). In addition, 
reference lists of included studies and review articles were hand searched to 
identify additional studies meeting selection criteria. 
Selection 
In the resulting pool of studies, two independent raters (A.R. and E.M.) identified 
studies that met the following inclusion criteria: 
1. Studies should contain patients who were hospitalized for acute MI.  
2. Anxiety (non-phobic) had to be measured within 3 months of hospitalization for 
acute MI using reliable and validated instruments to assess anxiety (either self-
report or interview-based). 
3. Studies had to be prospective in nature with at least 6 months follow-up and 
endpoints had to contain: all cause mortality, cardiac mortality, and/or cardiac 
events (e.g. hospitalization for unstable angina pectoris (UA), revascularization) in 
combination with mortality and/or recurrent MI, using a reliable and valid 
assessment strategy. 
4. Studies had to present original data (e.g. reviews and editorials were excluded). 
During the selection procedure, in case of disagreement between the two 
independent raters, the four investigators discussed the difference of opinion until 
consensus was reached. Regarding multiple reports on the same dataset, only one 
paper was included based on endpoint and follow-up period, preferring hard 
medical endpoints (e.g. mortality) and longer follow-up periods. Two studies 
presented an analysis on a combined sample of MI and UA patients and we also 
included these studies [18,30]. Data derived from patients randomized to placebo 
from a blind placebo-controlled medication trial in which anxiety was measured as 
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part of an ancillary study, was included [31]. If necessary, the coordinators of the 
eligible studies were asked for details.   
The following aspects of methodological quality were evaluated: sample size, 
study population (e.g. did the researchers include specific in-/exclusion criteria 
such as gender or disease severity), percentage lost to follow-up, follow-up 
duration and multivariable adjustment. We did not weigh the contribution of each 
study to the meta-analysis on the basis of quality scoring for there are no validated 
measures of quality and the use of subjective rating scales may lead to bias [32]. 
Endpoint 
The endpoint was all-cause mortality, cardiac mortality and/or cardiac events.  
Quantitative data synthesis 
Data from all studies were pooled using the program Comprehensive Meta-
Analysis version 2. To pool data across studies, we converted the time-related data 
into simple 2 x 2 tables. Thus, for all studies, irrespective of the presented effect 
measure (i.e. odds ratio (OR) or hazard ratio (HR)), data were converted into 
(unadjusted) dichotomous outcomes. Subsequently, ORs and 95% confidence 
intervals (CI) were calculated. The fixed and the random effect method (REM) 
were used to generate summary estimates of ORs. The appropriateness to combine 
results was tested with the I² test, which shows the proportion of total variance 
explained by heterogeneity. If I² was found to be less than 25% it was considered 
as low [33] and variation in the results of different studies thought to be due to 
chance alone [29]. In that case we based our main conclusions on the OR reported 
by the fixed effect method (FEM). We provided both estimates in the results 
section for the purpose of completeness.  
In two studies [11,27], more than one measure of anxiety was included. In these 
cases the most representative measure of anxiety (i.e. State Trait Anxiety Inventory 
(STAI)) as compared to the anxiety measures in other included studies was chosen. 
In three studies [11,31,34], anxiety symptoms were presented as a continuous 
variable. In these cases, the number of patients above and below the established 
cut-off point of the anxiety scale was estimated using the reported mean anxiety 
score and standard deviation based on the assumption of normal distribution. For 
studies using the STAI [11,31] a cut-off score ≥ 44 was chosen. For the study of 




author to one of the authors of the current study (P.d.J.). In two studies [9,27], the 
number of anxious and non-anxious patients in the event versus non-event group 
was calculated from the given OR or HR. The study of Pedersen et al. [35] was 
excluded based on the questionnaire used, namely the Trauma Symptom Checklist, 
which intends to measure traumas. Moreover, one study that measured anxiety 
before the MI was excluded [36].  
If study outcomes were heterogeneous based on the I2 test, the possible effects of 
follow-up duration, year of data collection, study population (MI versus MI and 
UA patients) and trait versus state anxiety would be studied. Differences in ORs 
between specified subgroups were assessed by comparing the pooled ORs using 
chi-squared analysis, comparing logarithms of the ORs. In order to evaluate the 
presence of publication bias, a funnel plot was constructed by plotting the effect 
measure against the inverse of its standard error.  
Additional information by personal communication 
Authors of four included studies were contacted for further information on study 
characteristics. Michael et al. confirmed that the reported endpoint consisted of 
ischemic cardiac events as verified by a cardiologist [30]. The study of Pfiffner and 
Hoffmann [37] was excluded because reported survival data was imprecise and we 
were not able to reproduce the reported OR. The article of Legault et al. [38] was 
excluded because reported data was limited and we could not compute an OR. We 
used the age- and gender-adjusted HR given in the paper of Frasure-Smith and 
Lespérance [27] to estimate the numbers of anxious and non-anxious patients in the 
event and non-event group.  
Results 
A flow diagram of the literature search is shown in Figure 1. The agreement rates 
(Cohen’s kappa) for the 2 steps in the selection procedure were 0.72 and 0.93 
respectively, indicating good to very good consistency of judgment by raters [39]. 
Twelve studies met selection criteria and study characteristics are shown in table 1. 
Fifteen analyses reported on the pre-specified endpoint (4 on all-cause mortality, 4 
on cardiac mortality and 7 on cardiac events). These studies described follow-up 
(on average 2.6 years) of 5750 MI patients. The mean age at time of the index MI 
ranged from 54 to 63 years and 82.5% of patients was male. The proportion of MI 
patients with anxiety symptoms at baseline ranged from 13.4% to 59.5%. Five 
analyses (2 on cardiac mortality and 3 on cardiac events) reported a significant 
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association between anxiety and prognosis in bivariate analysis. In 2 studies the 
association was no longer significant when controlling for demographic (e.g. age, 
gender) and clinical (e.g. disease severity) variables. Three analyses, 2 reporting on 
the association between anxiety and cardiac mortality or recurrent MI and one 
reporting on cardiac mortality, remained significant in multivariable analysis 
(Table 2).  
Figure 1: Flow chart of literature search 
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Mayou (23) MI 347 63 73 HADS-A ≤3 18.5  0 All-cause mortality 1.5 State 1994  No 
Carinci (9) 
 
MI 2449 NA 88 CBAHF 
Anxiety 
subscale  
≤3 30.1 0 All-cause mortality 0.5 State 1989 No 
Denollet (40) MI 105 54 
 
100 STAI 21-42 49.5 0 Cardiac + all-cause 
mortality 
3.8 Trait 1986 No 
Lane (22) 
 
MI 288 63 75 STAI 2-15  26.1 0 Cardiac + all-cause 
mortality 
3.0 State  1997  No 
Frasure-Smith (27) MI 896 59 74 STAI  During hospital 
admission 
13.4 2.9 Cardiac mortality 5.0 State 1991 Yes 
Denollet (41) MIa 87 55 93 STAI ≤60 31.0 0 Cardiac mortality + 
cardiac eventsc 
7.9 State 1985 Yes  
Ahern (31) MIb 353 59 83 STAI 6 to 60  22.1 0 All-cause 
mortality/cardiac 
arrest 
1.0 State  1983 No 
Strik (26) First MI 169 58 100 SCL-90 
Anxiety 
subscale 
30 59.5 0 Cardiac eventsc 3.4 State 1994  Yes 
 
 
Benninghoven (11) MI 76 NA 80 STAI <7 30.3 0 Cardiac eventsd 2.6 State  1999  No 
Michael (30) First MI/UA  65 60 46 HADS-A During hospital 
admission 
26.2 0 Cardiac ischemic 
events  
0.5 State NA No 
Frasure-Smith (18) MI/UA 804 60 81 HADS-A 2 months after 
discharge 
41.4 <1.0 Cardiac eventse 2.0 State 1999 Yes 





19.8 9.0 Cardiac eventsf 0.5 State  1996 No 
  
MI=myocardial infarction; HADS-A=Hospital Anxiety and Depression Scale –Anxiety subscale; NA=not available; UA=unstable angina; CBAHF=Cognitive Behavioral 
Assessment Hospital Form; STAI=State Trait Anxiety Inventory; SCL=Symptom Check List; STPI=State Trait Personality Inventory. 
  
a = Global left ventricular ejection fraction (LVEF) ≤50%  
b = Patients at risk for sudden death (≥10 ventricular premature complexes/hour or ≥5 episodes of nonsustained ventricular tachycardia) 
c = Cardiac death or recurrent MI 
d = Cardiac death, MI or revascularization 
e = Cardiac death, MI, survived cardiac arrest, nonelective revascularization 
f = Cardiac mortality, MI or unstable angina 




















































Frasure-Smith (27) Cardiac mortality 1.21 (1.01-1.46) 1.14 (0.93-1.38) Age, gender, educational level, daily smoking, previous MI, thrombolytic treatment 
at index admission, Q-wave MI, Killip class >1, revascularization at index 
admission, LVEF, antidiabetic medication and β-blockers. 
Denollet (41) Cardiac mortality 3.70 (1.10-12.40) 4.66 (1.20-18.17)a,c LVEF≤30% 
Denollet (41) Cardiac events 3.40 (1.20-9.60) 3.69 (1.27-10.70) a,c LVEF≤30% 
Strik (26) Cardiac events 2.76 (1.09-7.01)b 2.79 (1.11-7.03)c Age, LVEF≤50%, depression, hostility, use of antidepressants.  
Frasure-Smith (18) Cardiac events 1.67 (1.18-2.37) 1.45 (0.95-2.22) Age, gender, education, current daily smoker, previous MI, CABG or angioplasty, 
LVEF <45%, CABG during index hospitalization, ≥ 1 coronary vessel with ≥ 50% 
blockage after index revascularization, BMI, fasting triglyceride level, diastolic 
blood pressure, calcium channel blockers, angiotensin-converting enzyme inhibitors, 
and statins. 
 
LVEF=left ventricular ejection fraction; MI=myocardial infarction; CABG=coronary artery bypass graft; BMI=body mass index. 
 
a = OR provided by Denollet 
b = Based on own calculations 




Mortality and cardiac events 
Twelve studies reported on the combined endpoint. Cardiac mortality was chosen 
as endpoint in case the study reported on more than one endpoint. The pooled OR 
for all-cause and cardiac mortality and cardiac events in 1649 anxious compared 
with 4101 non-anxious MI patients was 1.36 (95% CI: 1.18-1.56; p<.001) in the 
FEM (Figure 2). No heterogeneity was observed in the model (I²=0.00%) and 
therefore no difference in the OR given by the FEM and REM. 
 
Figure 2: Association between anxiety and adverse outcomes 
 
The pooled OR for all-cause mortality in 925 anxious compared with 2241 non-
anxious MI patients was 1.47 (95% CI: 1.02-2.13; p=.04) in the FEM and 1.53 (95% 
CI: 0.95-2.46; p=.08) in the REM. For cardiac mortality, the pooled OR comparing 
265 anxious with 1072 non-anxious MI patients was 1.23 (95% CI: 1.03-1.47; 
p=.02) in the FEM and 1.33 (95% CI: 0.89-1.98; p=.16) in the REM.  
Although the included events varied across studies, all studies reporting on cardiac 
events included cardiac death and recurrent MI as endpoint. The pooled OR for 
cardiac events in 579 anxious compared with 1075 non-anxious MI patients was 
1.71 (95% CI: 1.31-2.23; p<.001) in the FEM and REM. 
Model Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Ahern, 1990 1,110 0,428 2,878 0,215 0,830
Denollet, 1995 1,910 0,526 6,931 0,984 0,325
Carinci, 1997 1,340 0,791 2,271 1,087 0,277
Denollet, 1998 3,650 1,087 12,255 2,095 0,036
Sydeman, 1999 1,470 0,460 4,694 0,650 0,515
Mayou, 2000 2,250 0,970 5,220 1,889 0,059
Lane, 2002 0,910 0,390 2,122 -0,218 0,827
Frasure-Smith, 2003 1,210 1,006 1,455 2,028 0,043
Strik, 2003 2,760 1,088 6,999 2,138 0,032
Michael, 2005 1,330 0,412 4,297 0,477 0,634
Benninghoven, 2006 1,350 0,498 3,657 0,590 0,555
Frasure-Smith, 2008 1,670 1,178 2,367 2,883 0,004
Fixed 1,356 1,177 1,562 4,224 0,000
0,1 0,2 0,5 1 2 5 10
Favours A Favours B
Meta Analysis
Heterogeneity I²=0.00% 
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The influence of anxiety on prognosis varied between endpoints. The impact of 
anxiety was significantly larger for cardiac events than for cardiac mortality 
(p=.04). The impact of anxiety on cardiac events was not significantly different 
from the impact on all-cause mortality (p=.52). 
Because the 12 studies reporting on the combined endpoint did not show 
significant heterogeneity, no further secondary analyses were conducted.  
A funnel plot of selected studies on the combined outcome suggests the presence of 
publication bias (Figure 3). Further inspection of the studies divided by endpoint 
revealed a possible bias for all-cause and cardiac mortality, but not for cardiac 
events (not shown).  
 








This is the first meta-analysis focusing on the association of anxiety with prognosis 
in heart disease patients. The results show a consistent association between anxiety 
and impaired prognosis after MI, with a 36% increased risk. This increased risk 
applies to both mortality (cardiac and all-cause) and cardiac events. Although the 
association between anxiety and cardiac events was significantly larger compared 
with that of cardiac death these results should be interpreted with caution because 
the pooled OR for cardiac death was based on only 4 studies. Overall, these 
findings support the conclusion that anxiety is associated with adverse medical 
outcomes after MI. 
In this meta-analysis, only one study reported on anxiety disorder, namely 
generalized anxiety disorder (GAD) [20]. In bivariate analysis, both self-reported 
symptoms and GAD were predictors of cardiac events. In multivariable analysis, 
only the association between GAD and prognosis remained significant. To date 
there is little information about the association between different anxiety disorders 
and cardiac outcome. Clearly, further research on the relationship between anxiety 
disorders and prognosis is warranted. 
There are several potential mechanisms that may help to explain the adverse 
association between anxiety and cardiac prognosis. Anxiety is potentially related to 
several pathophysiological processes in MI patients, including arrhythmic 
mechanisms [42] and dysfunction of the autonomic nervous system, such as 
reduced baroflex cardiac control [43] and reduced heart rate variability [44]. 
Theoretically, it may be that anxiety has a more influential role in electrical 
instability rather than in atherosclerotic or vascular disease conditions. In two 
studies cardiac arrest was included as endpoint [18,31]. One study found a 
significant association between anxiety and cardiac events (including survived 
cardiac arrest) [18] and the other found no association between anxiety and all-
cause mortality or cardiac arrest in patients at risk of sudden death [31]. However, 
both studies did not assess the association between anxiety and cardiac arrest 
specifically. More research is needed to the association of anxiety with arrhythmic 
mechanisms. 
In addition, a behavioral pathway of depression influencing prognosis is unhealthy 
behavior, like less compliance, smoking, unhealthy diet and inactivity [5]. This 
may also hold for anxious patients. Reversely, it is possible that anxious patients 
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seek more help from their doctors and try to improve their medical status [11]. 
However, Benninghoven et al. found that patients with higher anxiety levels 
showed neither better medication compliance nor had more contact with their 
cardiologists [11]. Given that some studies have found a protective effect of 
anxiety on outcome [25] it might be that it is anxiety in combination with 
nonprotective patient behavior that leads to worse prognosis, possibly due to an 
avoidant coping strategy [11] or social inhibition [45]. Further research regarding 
the behavioral and pathophysiological mechanisms responsible for the relationship 
between anxiety and prognosis is warranted. 
The prognostic association between anxiety and prognosis after MI seems smaller 
than that of depression [5], but larger as compared to the effects of anger and 
hostility. A recent meta-analysis showed that anger and hostility were associated 
with a 24% increased risk of poor prognosis in CHD patients [46]. Overall, these 
results show that various psychological factors, of which depression is probably the 
most important one, are consistently associated with adverse outcome in heart 
disease patients.  
It is important to assess the extent to which the association between anxiety and 
prognosis is independent of other clinical and psychological variables, such as 
depression. Studies have found rather mixed results, with some studies retaining 
depression [27] and others anxiety [15,26]. In addition, anxiety and depression 
have a moderate to strong correlation [47], yet anxiety and depression also have 
distinctive features [47]. It is possible that anxiety and depression are both part of a 
larger and more stable factor influencing prognosis in heart disease patients, like 
negative affectivity [47] or Type D personality (a combination of negative 
affectivity and social inhibition) [45].  
Somatic symptoms of depression such as fatigue are known to be related to disease 
severity [48]. In a meta-analysis on the association between depression and CHD 
prognosis, adjustment for left ventricular function reduced the relative risk with 
almost 50% [49]. On the contrary, disease severity adjusted ORs of the association 
between anxiety and medical prognosis after MI are only slightly or not attenuated 
[18,26,27]. This could indicate that the association between anxiety and medical 
outcome is less confounded by disease severity as compared to depression. 
Results of this meta-analysis indicate that treatment of distressed MI patients 




improve medical prognosis in depressed MI patients [50-51], perhaps because 
related anxiety was not treated [47]. There is a need for more behavioral medicine 
programs performing clinical outcomes research [52], in which various risk factors 
(e.g. depression, anxiety and hostility/anger) should be targeted.  
The results need to be considered in light of the study limitations. One of the most 
important limitations in conducting a meta-analysis is the inevitability of 
combining data from studies that are not equally designed. Patient samples were 
heterogeneous regarding gender and disease severity, and follow-up duration 
differed substantially across studies. However, the results of the included studies 
were quite homogeneous and it therefore seems that the finding of a significant 
prospective association between anxiety and CHD prognosis is robust.  
Anxiety is a very heterogeneous emotion and individuals may experience different 
kinds of anxiety symptoms. In order to limit heterogeneity we excluded studies on 
phobia and post traumatic stress disorder. Still, it remains unclear which aspects of 
anxiety contribute to cardiac outcomes. Further, 6 studies measured anxiety using 
the STAI. Research has shown that the STAI does not clearly differentiate anxiety 
from depression [53]. There is a need for more research to the construct of anxiety, 
its core features and development of new instruments. An additional limitation is 
the lack of temporal information about onset of anxiety. We do not know if 
included patients became anxious as a result of their MI or were already anxious 
prior to developing CHD. Although studies suggest an association between anxiety 
and heart disease in initially healthy persons as well [8], more research should 
focus on this topic and the possible differences between these groups. Another 
limitation is that two studies had to be excluded because of insufficient data. Of 
these studies, one reported a significant [37] and one reported a non-significant [38] 
effect of anxiety on outcome. Another limitation concerns the proneness of meta-
analyses to publication bias. We tried to minimize important sources of publication 
bias by including both non-English and nonpublished work in our literature search. 
We found a possible publication bias for mortality suggesting that the association 
between anxiety and mortality might be smaller than reported here. However, for 
the largest association found in this meta-analysis, namely between anxiety and 
cardiac events, we did not find indications of publication bias. 
Since the existing literature is quite small and contains several limitations, there is 
a need for further research to the association of anxiety and cardiac prognosis in MI 
Anxiety symptoms and prognosis after MI 
 
65 
patients. In the future, when more studies are published on this subject, this meta-
analysis should be brought up to date.  
In summary, post-MI anxiety is consistently related to adverse cardiac events in 
bivariate analyses. Findings are homogeneous and reliable, although more research 
is needed to assess the extent to which this association is independent of other 
psychological and clinical variables. The association between anxiety and outcome 
seems less strong than it is for depression, however, it might be less confounded by 
disease severity. The results from this study indicate the need for future research 
directed to the association between anxiety and prognosis after MI, to the 
identification of the underlying processes by which anxiety contributes to cardiac 
prognosis and to the testing of interventions to alleviate the associated risk. 
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Generalized anxiety disorder after acute myocardial 
infarction as a predictor of cardiac events and all-
cause mortality over 10 years 







Objectives: To evaluate the association between generalized anxiety disorder 
(GAD) and cardiac events and all-cause mortality in myocardial infarction (MI) 
patients, independent from depression. Background: Most studies that addressed 
the relationship between anxiety and cardiac disease have used questionnaires to 
measure anxiety. No study assessed the prognostic impact of GAD, diagnosed with 
a formal psychiatric interview, after acute MI on adverse outcomes. Methods: 
Patients with acute MI (n=438) were recruited between September 1997 and 
September 2000 and were followed up until December 2007. Measurements 
included demographic and clinical data. GAD and depression after the MI were 
assessed by means of the Composite International Diagnostic Interview at 3 
months post-MI. The endpoint consisted of all-cause mortality and cardiac related 
readmissions over a period of 10 years. Results: During the follow-up period, 198 
patients died or were readmitted at least once. GAD was associated with an 
increased rate of adverse events after adjustment for age and gender (hazard ratio: 
1.94; 95% confidence interval: 1.14-3.30; p=0.01). Additional adjustment for 
measures of cardiac disease severity and depression did not change the results. 
Conclusions: MI patients with GAD were at an almost 2-fold increased risk of 
cardiac events and all-cause mortality over a mean follow up of 5.7 years compared 
to patients without GAD. This association was independent from demographic and 
clinical variables and depression. More research is needed to identify the 
mechanisms through which GAD is associated with an adverse prognosis following 
MI.  




During the last decades, substantial research has focused on the association 
between psychological distress and heart disease. Most studies have focused on the 
role of depression. Several meta-analyses indicate that depression is a risk factor 
for the development of coronary heart disease (CHD) in the general population [1,2] 
and is associated with adverse outcomes in patients with CHD [3]. Less research 
has focused on the role of anxiety. Like depression, anxiety is strongly related to 
CHD. Anxiety in initially healthy persons is associated with a 26% increased risk 
of developing CHD [4]. In patients with acute myocardial infarction (MI), the 
prevalence of elevated symptoms of anxiety is on average 30% [5]. Moreover, in a 
meta-analysis including 12 studies covering 5,750 MI patients, it was shown that 
anxiety is associated with a 36% increased risk of new cardiovascular events or 
mortality [5].  
A significant limitation of the studies conducted this far is that most have used 
questionnaires to assess the presence of elevated symptoms of anxiety. Although 
questionnaires can be used as screening tools [6-9] they are not sufficient to 
diagnose an anxiety disorder. Furthermore, questionnaires are inadequate in 
distinguishing between emotional disorders, specifically between anxiety and 
depression [6,10,11]. To our knowledge, only two studies have assessed the 
association between anxiety assessed with a diagnostic interview and adverse 
cardiac prognosis, but these studies were both in patients with CHD [6,12]. Thus, 
to date no study assessed the prognostic impact of generalized anxiety disorder 
(GAD) after acute MI. Therefore, we evaluated the prognostic impact of GAD after 
MI on new cardiac events and mortality up till 10 years after the MI using a formal 
psychiatric interview. As GAD and depression are closely associated [13-15] we 
specifically analyzed whether its impact is independent from depression. 
Methods 
Patients 
Patients were included from the Depression after Myocardial Infarction (DepreMI) 
study. DepreMI was a naturalistic cohort study evaluating the effects of depression 
after MI on adverse cardiac outcomes. Details of this study are described elsewhere 
[16,17]. Previous publications on DepreMI have focused on depression and did not 
examine anxiety. Eligible patients admitted consecutively for MI at four hospitals 




participate. At least two of the following three criteria for MI had to be met: 1) a 
documented increase in cardiac enzyme levels, 2) typical electrocardiographic 
changes, 3) at least 20 minutes of chest pain. Exclusion criteria were the presence 
of another somatic disease likely to influence short-term survival, MI during 
hospital admission for another reason (except unstable angina), and being unable to 
participate in study procedures. The institutional review board of each participating 
hospital approved the protocol and all participants signed informed consent.  
Assessment of GAD 
GAD is characterized by a period of at least six months with prominent tension, 
worry and feelings of apprehension about every day events and problems. 
Associated symptoms are symptoms of autonomic arousal and other somatic or 
cognitive symptoms of tension and worry [18]. The presence of an International 
Classification of Diseases (ICD)-10 diagnosis of GAD after the MI was assessed 
by means of the Composite International Diagnostic Interview (CIDI) version 1.1 
[19], which was administered 3 months post-MI in order to reduce possible 
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The ICD-10 criteria of GAD 
A. A period of at least six months with prominent tension, worry and feelings of apprehension, about 
every-day events and problems.                                                                                                                   
B. At least four symptoms out of the following list of items must be present, of which at least one 
from items (1) to (4). 
Autonomic arousal symptoms 
1.  Palpitations or pounding heart, or accelerated heart rate.   
2.  Sweating.      
3.  Trembling or shaking.            
4. Dry mouth.  
Symptoms concerning chest and abdomen 
5. Difficulty breathing.                             
6.  Feeling of choking. 
7.  Chest pain or discomfort.         
8.  Nausea or abdominal distress.  
Symptoms concerning brain and mind 
9.  Feeling dizzy, unsteady, faint or light-headed.                                                                            
10.  Feelings that objects are unreal, or that one's self is distant or "not really here".    
11.  Fear of losing control, going crazy, or passing out.         
12.   Fear of dying. 
General symptoms 
13. Hot flushes or cold chills.               
14.  Numbness or tingling sensations. 
Symptoms of tension 
15.  Muscle tension or aches and pains.      
16.  Restlessness and inability to relax.  
17.  Feeling keyed up, or on edge, or of mental tension.   
18.  A sensation of a lump in the throat, or difficulty with swallowing. 
Other non-specific symptoms 
19. Exaggerated response to minor surprises or being startled.        
20.  Difficulty in concentrating, or mind going blank, because of worrying or anxiety.    
21.  Persistent irritability.    





Assessment of the covariates 
Age, gender, clinical characteristics, cardiac risk factors, and comorbidities were 
assessed during hospitalization for the index-MI and from hospital charts. Left 
ventricular ejection fraction (LVEF) was assessed by echocardiography, 
radionuclide ventriculography, gated single photon emission computed tomography, 
magnetic resonance imaging, angiography or clinical assessment. The presence of 
an ICD-10 diagnosis of a post-MI depressive episode was assessed with the CIDI 
at 3 months after the MI.   
Assessment of adverse outcomes 
Data concerning mortality were obtained up till 31 December 2007 from the Dutch 
Central Bureau of Statistics by linkage to the municipal personal records database. 
Data concerning hospital admissions in the period between the index-MI and 31 
December 2007 came from the Dutch national registry of hospital discharges and 
were obtained from the Dutch Central Bureau of Statistics by linkage to the 
municipal personal records database. Hospital readmissions with ICD-9 codes 410, 
411, 413, 414 (ischemic heart disease), 427.1, 427.4, 427.5 (cardiac arrhythmia), 
428, 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 
404.93 (heart failure), 433, 434, 435, 437.0, 437.1 (cerebrovascular disease) and 
440, 443.9 (peripheral vascular disease) were included as cardiac events. 
The follow-up period for adverse outcomes started at the CIDI interview at 3 
months after the MI and ended at 31 December 2007. This timeframe was chosen 
to optimize the number of potential events. Only deaths and cardiac related 
readmissions occurring between the CIDI interview at 3 months after the MI and 
31 December 2007 were considered as adverse outcomes.  
Statistical analyses 
Baseline demographic and clinical characteristics were compared with Chi-square 
and student t-test. For this purpose, non-normally distributed continuous variables 
were log-transformed. We calculated event-free survival-time as time to first event 
or death. If no event or death occurred, the patient was censored at 31 December 
2007. Using Cox regression we evaluated whether event-free survival was different 
for patients with and patients without GAD after the MI. In the basic model, 
adjustments were made for age and gender. Additionally, we adjusted for LVEF, 
and diagnosis of post-MI depression, because these have been shown to be 
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associated with worse cardiac prognosis. In sensitivity analyses, adjustments were 
made for other clinical variables that significantly predicted cardiac events and 
mortality in the present sample, namely anterior site of the index MI, and history of 
MI and peripheral vascular disease. For all analyses, SPSS 14 was used and 
significance level was set at 0.05, two-tailed. 
Results 
For this study, 1,166 patients were assessed for eligibility. Of these, 882 patients 
were eligible of whom 528 (59.9%) signed an informed consent. Of the 461 
patients with a CIDI interview, 23 were excluded due to missing information on the 
endpoint, leaving 438 patients included for further analyses.  
Generalized anxiety disorder 
Three months after the index MI, 24 patients (5.5%) met the criteria for GAD. 
Patients with GAD were less likely to be treated with percutaneous transluminal 
coronary angioplasty (p=0.03) and more likely to have a history of MI (p=0.02) 
compared with patients without GAD. Of the patients with GAD, 12 (50%) had a 
concurrent depressive episode (table 1). During follow-up, 15 (62.5%) patients 
with GAD had a cardiac event or died compared with 183 (44.2%) patients without 




Table 1: Comparison of patients with and without GADa,b 
 No GAD (n=414) GAD  (n=24) p 
Age, years mean (SD) 60.7 (11.4) 58.3 (10.9) 0.33 
Male gender  334 (80.7) 20 (83.3) 0.75 
Primary school only  78 (18.8) 6 (25.0) 0.46 
Living alone  58 (14.0) 5 (20.8) 0.35 
Current smoking  194 (51.3) 14 (63.6) 0.26 
LVEF <40  97 (23.5) 7 (29.2) 0.53 
Anterior site of MI  130 (31.4) 8 (33.3) 0.84 
PTCA  100 (26.3) 1 (4.8) 0.03 
CABG  12 (3.2) 2 (9.5) 0.12 
Killip class 2  13 (3.2) 2 (8.3) 0.18 
CPK-mb mean (SD)c 117.8 (122.9) 121.7 (182.2) 0.16 
CPK mean (SD)c 1322.8 (1319.2) 1818.9 (3010.8) 0.48 
History of MI  53 (12.8) 7 (29.2) 0.02 
History of cerebral vascular disease  18 (4.3) 1 (4.2) 0.97 
History of peripheral vascular disease  27 (6.5) 3 (12.5) 0.26 
Family history of cardiovascular disease  155 (37.4) 9 (37.5) 1.00 
Diabetes 37 (8.9) 4 (16.7) 0.21 
Hypertension  118 (28.5) 3 (12.5) 0.09 
Hypercholesterolemia  144 (34.8) 7 (29.2) 0.57 
Body mass index (SD) 26.7 (4.0) 26.8 (4.1) 0.92 
Depression  53 (12.8) 12 (50.0) <.001 
 
CABG= coronary artery bypass graft; CPK= creatinine phosphokinase; GAD= generalized anxiety disorder; 
LVEF= left ventricular ejection fraction; MI= myocardial infarction; PTCA= percutaneous transluminal coronary 
angioplasty. 
 
a = Values are expressed as n (%) of patients unless otherwise indicated. 
b = T-test for continuous variables and Chi-square for dichotomous variables were used. 
c = Log-transformations of CPK were used for the t-test. 
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Figure 1: Adverse outcomes in patients with and without GAD and depression 
 
 
Percentage of cardiac events and all-cause mortality in patients with versus without GAD and patients with versus 
without depression 
 
Predictors of cardiac events and mortality 
During the follow-up period, 198 patients met the combined endpoint of all-cause 
mortality and cardiac events with a mean (standard deviation) follow-up period of 
5.7 (3.1) years. Patients who had an event during the follow-up period were more 
likely to be older (p<.001), living alone (p=0.04), to have an anterior MI, (p=0.02), 
a LVEF lower than 40 (p<.001), and a history of MI (p=0.001), cerebrovascular 















Table 2: Comparison of patients with and without an adverse prognosisa,b 







Age, years mean (SD) 61 (11.4) 58 (10.8) 63 (11.5) <.001 
Male gender  354 (80.8) 198 (82.5) 156 (78.8) 0.33 
Primary school only  84 (19.2) 42 (17.5) 42 (21.2) 0.33 
Living alone 63 (14.4) 27 (11.3) 36 (18.2) 0.04 
Current smoking  208 (52.0) 114 (51.1) 94 (53.1) 0.69 
LVEF <40  104 (23.8) 40 (16.7) 64 (32.5) <.001 
Anterior site of MI  138 (31.5) 64 (26.7) 74 (37.4) 0.02 
PTCA  101 (25.2) 61 (27.4) 40 (22.5) 0.26 
CABG  14 (3.5) 10 (4.5) 4 (2.2) 0.23 
Killip class 2  15 (3.4) 6 (2.5) 9 (4.6) 0.24 
CPK-mb mean (SD)c 118.0 (126.6) 117.9 (132.0) 118.1 (119.9) 0.75 
CPK mean (SD)c 1350.0 (1461.0) 1347.2 (1523.8) 1353.3 (1384.9) 0.70 
History of MI  60 (13.7) 21 (8.8) 39 (19.7) 0.001 
History of cerebral vascular disease  19 (4.3) 5 (2.1) 14 (7.1) 0.01 
History of peripheral vascular disease  30 (6.8) 7 (2.9) 23 (11.6) <.001 
Family history of cardiovascular 
disease  
164 (37.4) 89 (37.1) 75 (37.9) 0.86 
Diabetes  41 (9.4) 18 (7.5) 23 (11.6) 0.14 
Hypertension  121 (27.6) 66 (27.5) 55 (27.8) 0.95 
Hypercholesterolemia  151 (34.5) 80 (33.3) 71 (35.9) 0.58 
Body mass index (SD) 26.7 (4.0) 26.7 (4.5) 26.7 (3.3) 0.98 
Depression  65 (14.8) 33 (13.8) 32 (16.2) 0.48 
GAD  24 (5.5) 9 (3.8) 15 (7.6) 0.08 
 
CABG= coronary artery bypass graft; CPK= creatinine phosphokinase; GAD= generalized anxiety disorder; 
LVEF= left ventricular ejection fraction; MI= myocardial infarction; PTCA= percutaneous transluminal coronary 
angioplasty. 
 
a = Values are expressed as n (%) of patients unless otherwise indicated. 
b = T-test for continuous variables and Chi-square for dichotomous variables were used. 
c = Log-transformations of CPK were used for the t-test. 
GAD as predictor of cardiac events and mortality 
Table 3 shows the association of GAD with adverse prognosis for different models. 
GAD was associated with cardiac events and mortality after adjustment for age and 
gender (figure 2). After additional adjustment for LVEF, GAD remained an 
independent predictor of adverse outcome. LVEF (hazard ratio (HR): 1.58; 95% 
confidence interval (CI): 1.17-2.14; p=0.003) and age (HR per year: 1.03; 95% CI: 
1.02-1.04, p<.001) were also significant predictors in this model. Adjustment for 
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post MI depression did not affect the association between GAD and cardiac events 
and mortality. Post-MI depression was not a significant predictor of adverse 
outcome in this model (HR: 1.20 95% CI: 0.80-1.80, p=0.38). In sensitivity 
analyses, in addition to age and gender, consecutive adjustment for history of MI, 
history of peripheral vascular disease, and anterior site of the index MI did not 
materially affect the association between GAD and adverse prognosis (table 3).  
 
Figure 2: GAD and cardiac events and all-cause mortality 
 
 
The association of GAD after MI with cardiac events and all-cause mortality adjusted for age and gender  





Table 3: Association of GAD with cardiac events and all-cause mortality 
Controlling for: HR (95% CI) p  
Age, gender 1.94 (1.14-3.30) 0.01 
Age, gender, LVEF 1.92 (1.13-3.28) 0.02 
Age, gender, depression 1.84 (1.06-3.17) 0.03 
Age, gender, history of MI 1.81 (1.06-3.09) 0.03 
Age, gender, history of peripheral vascular disease 1.95 (1.15-3.31) 0.01 
Age, gender, anterior site of index MI 1.89 (1.11-3.22) 0.02 
 
CI= confidence interval; GAD= generalized anxiety disorder; HR: hazard ratio; LVEF= left ventricular ejection 
fraction; MI= myocardial infarction. 
 
Discussion 
This study is the first to assess the prognostic impact of GAD after acute MI on 
cardiac events and all-cause mortality up till 10 years after the index event. Patients 
with GAD were at an almost two-fold increased risk of adverse prognosis after 
adjustment for age, gender, and several cardiac disease severity parameters.  
Our findings are in concordance with those of other studies that investigated the 
impact of GAD in patients with stable heart disease [6,12]. In the present study, 
adjustment for depression did not influence the association of GAD with adverse 
prognosis. This is consistent with other studies assessing the association between 
anxiety and cardiac events independent from depression [12,20].  
Several potential biological mechanisms might explain the association between 
GAD and CHD. For instance, several studies found a relationship between anxiety 
and indicators of autonomic dysfunction in MI patients, including reduced heart 
variability [21] and reduced baroflex cardiac control [22]. Anxiety is also 
associated with increased platelet activity [23] and markers of inflammation [24], 
in otherwise healthy individuals. Another mechanism that may explain the 
association between anxiety and CHD is unhealthy behavior, like physical 
inactivity, an unhealthy diet, and smoking. Anxiety is related to an unhealthy 
lifestyle in individuals at risk of CHD [25]. In addition, anxiety following MI is 
associated with lower adherence to various risk-reducing recommendations, such 
as smoking cessation [26,27]. However, in a recent study, a variety of potential 
mediating mechanisms, including levels of cortisol and norepinephrine, heart rate 
variability, inflammation, smoking, medication nonadherence, and physical 
inactivity, could not explain the association between GAD and cardiovascular 
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events in patients with stable CHD [12]. More research is needed to identify the 
mechanisms through which GAD leads to an adverse prognosis.  
In the present study, the association between GAD and adverse prognosis could not 
be explained by several cardiac disease severity parameters, including LVEF and 
anterior site of the index MI. However, it is still possible that the association is 
confounded by disease severity, especially since some symptoms of GAD, such as 
palpitations and chest pain, might also be symptoms of heart disease. Further, 
patients with GAD might worry about their health and be more likely to consult 
their doctor and be admitted to the hospital with cardiac complaints. This might 
explain part of the association between GAD and cardiac related hospital 
readmissions. To minimize this effect, we excluded hospital admissions for chest 
pain only from our analyses.  
Although it has not been specifically studied in patients with heart disease, GAD 
can be effectively treated with psychopharmacological treatment, e.g. selective 
serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors, and 
cognitive behavioral therapy [28]. Unfortunately, many patients do not receive 
adequate treatment [28]. Besides the impact of anxiety on disability and decreased 
quality of life, clinicians should be aware of the finding that GAD is associated 
with an increased risk of cardiac events and mortality following MI.   
Strength of the present study is the use of a standardized diagnostic interview to 
assess the presence of GAD in this sample of patients with acute MI. Other 
strengths are the long follow-up period and the objective and comprehensive 
assessment of cardiac related readmissions and mortality, resulting in a sufficient 
number of events. A limitation is the relatively small sample size, which limits our 
ability to adjust for potential covariates simultaneously.  
In summary, this study showed that in patients with acute MI, GAD was associated 
with an almost 2 fold increased risk of new cardiac events and mortality. This 
association remained significant after adjustment for age, gender, measures of 
disease severity and depression. More research is needed to identify the 
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Somatic/affective symptoms, but not 
cognitive/affective symptoms, of depression after 
acute coronary syndrome are associated with 12-
month all-cause mortality 
Roest AM, Thombs BD, Grace SL, Stewart DE, Abbey SE, de Jonge P. 






Background: Symptom dimensions of post myocardial infarction (MI) depression 
may be differently related to prognosis. Somatic/affective symptoms appear to be 
associated with a worse cardiac outcome than cognitive/affective symptoms. We 
examined the relationship between depressive symptom dimensions following 
acute coronary syndrome (ACS) and both disease severity and all-cause mortality. 
Methods: Patients (n=913) who had unstable angina pectoris or MI were recruited 
from 12 coronary care units between 1997 and 1999. Measurements included 
sociodemographic and clinical data and the Beck Depression Inventory (BDI). 
Endpoint was all-cause mortality at 12-month follow-up. Results: Principal 
component analysis revealed two components, somatic/affective and 
cognitive/affective symptoms of depression. Somatic/affective symptoms of 
depression (odds ratio (OR): 1.49; 95% confidence interval (CI): 1.23-1.81; 
p<0.001) but not cognitive/affective symptoms (OR: 0.92; 95% CI: 0.75-1.12; p= 
0.40) were related to a higher Killip class. Fifty-one patients died during the 
follow-up period. When controlling for index event, history of MI, Killip class, 
diabetes, gender and age, there was a significant association between the 
somatic/affective component (OR: 1.92; 95% CI: 1.36-2.71; p<0.001) and 
mortality. The cognitive/affective component was not related to mortality (OR: 
1.07; 95% CI: 0.75-1.52; p= 0.73). Limitations: Time to death was not available. 
Conclusions: This study showed that only somatic/affective depressive symptoms 
were associated with disease severity and all-cause mortality in ACS patients. 
More research is needed to evaluate the differential associations of 
somatic/affective and cognitive/affective depressive symptoms with cardiac 
outcomes and the underlying mechanisms.  




During the last decades, substantial research has focused on the association 
between depression after myocardial infarction (MI) and prognosis, with most 
studies concluding that depression is related to adverse outcome [1-4]. The authors 
of one meta-analysis concluded that depression is a risk factor for poor prognosis 
in patients with coronary heart disease (CHD) [2]. The authors of several other 
systematic reviews and meta-analyses, however, cautioned that there is not 
sufficient evidence to consider depression an independent risk factor due to 
methodological issues in existing prognostic studies, including incomplete 
adjustment for conventional risk factors and cardiovascular disease severity [1,3,4]. 
The authors of one of the meta-analyses, for example, noted that adjustment for left 
ventricular ejection fraction (LVEF) in 8 studies reduced risk estimates of 
depression on cardiac outcomes by almost 50%, but only 8 of 34 studies in their 
review adjusted for LVEF [4]. Therefore, it is still unclear whether depression is an 
independent risk factor or if the relationship between depression and adverse 
prognosis is influenced by inadequate adjustment for confounding due to 
traditional risk factors and cardiovascular disease severity.  
Recently, several studies have reported that somatic/affective symptoms of 
depression (e.g., fatigue, sleep problems, and poor appetite), but not 
cognitive/affective symptoms (e.g., shame, guilt and negative self-image), were 
related to adverse cardiac prognosis following an MI [5-7]. Somatic/affective 
symptoms were associated with disease severity, but after controlling for disease 
severity the association of somatic/affective symptoms with cardiac prognosis 
remained statistically significant [5-7]. This finding has also been reported among 
patients with chronic heart failure [8] and women with suspected myocardial 
ischemia [9]. In each of these studies, somatic/affective symptoms, but not 
cognitive/affective symptoms, were statistically significantly related to cardiac 
outcome. However, in each study, the confidence intervals for risk related to 
somatic/affective and cognitive/affective symptoms overlapped.  
In the present study, we investigated the associations of somatic/affective and 
cognitive/affective symptom dimensions of depression among acute coronary 
syndrome (ACS) patients with disease severity and all-cause mortality. We 
hypothesized that somatic/affective depressive symptoms would be associated with 




severity, only the somatic/affective dimension of depressive symptoms would be 
associated with adverse outcome. 
Methods 
Study design and patient population 
This was a prospective study following patients admitted with ACS to 12 coronary 
care units (CCU) across South-central Ontario, Canada, for 1 year. The methods of 
the study have been described previously [10]. Participants (18 years and older) 
who were diagnosed with a confirmed MI or unstable angina pectoris (UA) after 
appropriate diagnostic tests were recruited between August 1997 and January 1999 
in the CCU by a research nurse on the 2nd to 5th day of hospitalization. Patients 
were excluded if they were medically too ill to complete assessment, or unable to 
read or speak English. At baseline, patients completed a self-reported questionnaire. 
They were followed up by mail at home 12 months later and asked to report on 
events in the intervening months. The original study protocol was approved by the 
Research Ethics Boards of the University of Toronto and University Health 
Network. Written informed consent was obtained from all study participants. 
Assessment of depressive symptoms 
Symptoms of depression were measured within the first week of hospital admission 
with the Beck Depression Inventory (BDI), a 21-item self-report measure 
developed to assess the presence and severity of depressive symptoms [11]. Each 
item is rated on a 0-3 scale with higher scores reflecting greater depressive 
symptomatology. The BDI is a valid and reliable measure of depressive symptoms 
in patients with cardiovascular disease [12].  
Clinical characteristics 
Killip class was used to indicate the severity of the ACS by assessing the presence 
of heart failure at the time of the index event. Killip class was defined as 1 versus 2 
and higher in concordance with other studies [10]. Killip class and history of 
previous MI were obtained from the patients’ medical records. Other health status 
variables, including somatic comorbidity (e.g. diabetes) and smoking status, were 
determined from a patient health questionnaire. Demographic variables included 
age, gender, marital status, education level, and family income.  
 




Endpoint was all-cause mortality at 12-month follow-up. For patients who did not 
return the 12-month follow-up questionnaire, their vital status was determined by 
contacting the patients’ family, or contacts listed in the initial data collection form, 
patients’ general practitioners, and patients’ specialist physicians. We did not have 
information on date of death.   
Statistical analysis 
Discrete and continuous variables were compared with the chi-square test and the 
independent-sample t-test between patients who were alive 12 months post-ACS 
and patients who died during this period. We assumed that the underlying 
constructs were correlated. Therefore, in concordance with Martens et al. [7], we 
used principal component analysis (PCA) with oblimin rotation to determine linear 
components existing in the data. A scree plot was used to identify the number of 
components. The Kaiser-Meyer-Olkin (KMO) test and Bartlett’s test of sphericity 
were applied as fit indices. The association between the identified components was 
investigated using the Pearson product-moment correlation coefficient. Binary 
logistic regression analyses were used to evaluate the association between the 
factor scores on depressive symptom components and Killip class and to predict 
all-cause mortality, based on the somatic/affective and cognitive/affective 
depressive symptom dimensions. In addition to the index event (MI or UA), we 
adjusted for potential predictors of mortality in these analyses, namely age, gender, 
diabetes, history of MI, and Killip class. The original BDI total scores were 
transformed to z-scores to be able to compare the association of the 
somatic/affective depressive symptom dimension and mortality with the 
association of the BDI total score with outcome. All statistical tests were 2-tailed, 
with p<0.05 denoting significance and were performed using SPSS version 17.0 for 
Windows (SPSS Inc., USA). 
Results 
In-hospital depression  
Of the original 913 patients, 28 were excluded due to incomplete BDI responses 
and 11 for missing information on survival status, leaving 874 patients to be 




or higher, which is comparable to previous research [1]. Table 1 shows 
demographic and clinical characteristics of the sample. 
Table 1: Demographic and clinical characteristicsa  
Characteristics All patients 




Alive at follow-up 
(n= 823) 
p 
Demographic variables     
Age, years (SD) 62 (11.9) 69 (10.7) 61 (11.9) <.001 
Gender (female) 301 (34.5) 17 (33.3) 248 (34.5) 0.86 
Married 642 (74.4) 34 (66.7) 608 (74.9) 0.19 
Education > high school 273 (32.0) 9 (18.8) 264 (32.8) 0.04 
Family income >$ 50,000 331 (44.3) 11 (26.8) 320 (45.3) 0.02 
Clinical characteristics     
Smoked in past 2 years 282 (33.3) 14 (28.6) 268 (33.6) 0.47 
Index diagnosis MI 465 (53.3) 29 (56.9) 436 (53.0) 0.60 
Killip class > 1 132 (16.0) 12 (25.5) 120 (15.4) 0.07 
Previous MI 277 (33.4) 28 (56.0) 249 (31.9) <.001 
History of CHF 34 (4.1) 4 (8.0) 30 (3.8) 0.15 
History of UA 362 (43.6) 28 (56.0) 334 (42.8) 0.07 
History of CABG 79 (9.5) 6 (12.0) 73 (9.4) 0.54 
History of PTCA 44 (5.3) 4 (8.0) 40 (5.1) 0.38 
History of TIA or CVA 30 (3.6) 3 (6.0) 27 (3.5) 0.35 
Diabetes 202 (25.0) 16 (34.0) 186 (24.5) 0.14 
Systolic blood pressure > 130 483 (57.8) 26 (52.0) 457 (58.1) 0.39 
 
SD= standard deviation; MI= myocardial infarction; CHF= congestive heart failure; UA= unstable angina pectoris; 
CABG= coronary artery bypass graft; PTCA= percutaneous transluminal coronary angioplasty; TIA= transient 
ischemic attack; CVA= cerebrovascular accident. 
 
aValues are expressed as n (%) of patients unless otherwise indicated 
 
Component structure 
The KMO test (0.93) and Barlett’s test of sphericity (p<0.001) showed that PCA 
was adequate for these data. Based on the criterion of Eigenvalue >1 and the 
screeplot, we determined the optimal number of factors to be 2. The total explained 
variance was 40%. There was a moderately positive correlation between the two 
components (r = 0.40, p<0.001). Based on previous research, the components were 
labeled cognitive/affective and somatic/affective symptoms of depression [5]. The 
factor loadings for each variable on each component are presented in Table 2.  
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Table 2: Pattern matrix of principal component analysis 
 
Depressive symptoms from BDI Cognitive/affective 
component 
Somatic/affective component 
1. Sadness 0.64  
2.  Pessimism 0.67  
3. Sense of failure 0.81  
4. Dissatisfaction 0.47 0.32 
5. Guilt 0.71  
6. Punishment 0.71  
7. Self-dislike 0.77  
8. Self-accusations 0.71  
9. Suicidal ideas 0.61  
10. crying 0.48  
11. Irritability  0.31 
12. Social withdrawal 0.56  
13. Indecisiveness 0.51  
14. Body-image change 0.34  
15. Work difficulty  0.72 
16. Insomnia  0.46 
17. Fatigability  0.71 
18. Loss of appetite  0.51 
19. Weight loss  0.44 
20. Somatic preoccupation  0.39 
21. Loss of libido  0.61 
 
BDI= Beck Depression Inventory 
 
Associations of depressive symptom components with Killip class  
In unadjusted logistic regression analyses, the somatic/affective depressive 
symptom component (odds ratio (OR): 1.44; 95% confidence interval (CI): 1.21-
1.72; p <0.001) but not the cognitive/affective component (OR: 1.08; 95% CI: 
0.90-1.28; p= 0.42) was related to Killip class. When both components were 
simultaneously entered into the model, somatic/affective symptoms of depression 
(OR: 1.49; 95% CI: 1.23-1.81; p <0.001) but not cognitive/affective symptoms 






Predictors of all-cause mortality 
Fifty-one patients died during the 12-month follow-up. Bivariate analyses showed 
that patients who died were more likely to be older (p< 0.001), to have a lower 
family income (p= 0.02), a lower education (p= 0.048) and to have experienced a 
previous MI (p= 0.001). When entering these potential confounders into a 
multivariate analysis, only age remained as an independent predictor of mortality. 
Depressive symptoms and mortality 
The somatic/affective symptom component (OR: 1.89; 95% CI: 1.47-2.44; p<0.001) 
but not the cognitive/affective component (OR: 1.15; 95% CI: 0.91-1.46; p= 0.25) 
(Table 3, models 1a and 1b) was associated with 12-month all-cause mortality. 
When the two symptom components were entered into the model simultaneously, 
the cognitive/affective component was not related to mortality (OR: 0.87; 95% CI: 
0.66-1.16; p= 0.35), whereas the association between the somatic/affective 
component and mortality remained statistically significant (OR: 2.01; 95% CI: 
1.52-2.65; p<0.001) (Table 3, model 2). When controlling for index event, history 
of MI, Killip class, diabetes, gender and age, the somatic/affective component (OR: 
1.92; 95% CI: 1.36-2.71; p<0.001) significantly predicted all-cause mortality, but 
the cognitive/affective component did not (OR: 1.07; 95% CI: 0.75-1.52; p= 0.73).  
Previous MI, older age and male gender were also significant independent 
predictors of mortality (Table 3, model 3). Because patients who died had a lower 
family income and a lower education, we also adjusted for these variables in a 
sensitivity analysis. However, further adjustment for these variables did not change 
the results. The BDI total score was also a significant predictor of all-cause 
mortality in unadjusted (1.47; 95% CI: 1.17-1.83; p=0.001) and adjusted analyses 
(OR: 1.77; 95% CI: 1.31-2.40; p<0.001), but the associations were somewhat 
smaller compared to the associations of the somatic/affective component with 
mortality. 
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Table 3: Predictors of all-cause mortality 
 
Predictor variables OR 95% CI p 
Model 1a    
Somatic/affective component 1.89 1.47-2.44 <.001 
Model 1b    
Cognitive/affective component 1.15 0.91-1.46 0.25 
Model 2    
Somatic/affective component 2.01 1.52-2.65 <.001 
Cognitive/affective component 0.87 0.66-1.16 0.35 
Model 3    
Somatic/affective component 1.92 1.36-2.71 <.001 
Cognitive/affective component 1.07 0.75-1.52 0.73 
Previous MI 2.69 1.38-5.23 <.001  
Index event MI 1.29 0.67-2.52 0.45 
Diabetes 1.03 0.51-2.08 0.94 
Killip class 0.80 0.35-1.82 0.60 
Age 1.07 1.03-1.11 <.001 
Female gender  0.42 0.20-0.88 0.02 
 
OR= odds ratio; CI= confidence interval; MI= myocardial infarction 
 
Discussion 
This study is the first to examine the associations between somatic/affective and 
cognitive/affective depressive symptoms with all-cause mortality in a large 
combined sample of patients who had experienced an MI or UA. The dimensional 
structure of depressive symptoms was similar to the structures found in earlier 
studies [5,7]. Somatic/affective depressive symptoms were associated with Killip 
class while cognitive/affective depressive symptoms were not. The 
somatic/affective depressive symptom dimension was an independent predictor of 
all-cause mortality 12 months after the index event in patients hospitalized for ACS. 
This was the case even after controlling for demographic and clinical variables, 
including disease severity. The cognitive/affective depressive symptom dimension 
was not associated with mortality. In addition, the effect of the BDI total score on 
mortality appeared to be completely attributable to the somatic/affective symptom 
dimension.  
These findings are in concordance with earlier studies that assessed the association 




prognosis in MI patients [5-7]. The findings of this study are also consistent with a 
recent study by Doyle et al. [13] that found that only a depression scale containing 
mostly fatigue items predicted major cardiac events in persons with ACS, whereas 
symptoms of anhedonia and depressive cognitions did not.  
There are multiple possible mechanisms which could explain the relationship 
between depressive symptoms and prognosis in ACS patients. One possible 
pathway of depression influencing prognosis is via unhealthy behavior, like 
smoking, less compliance, unhealthy diet and inactivity [1]. For example, in the 
Heart and Soul study, lifestyle factors accounted for almost 50% of the association 
between depression and new cardiac events in stable CHD patients, mainly through 
lack of physical activity [14]. Physiological mediators in the relation between 
depression and adverse cardiac prognosis may be increased platelet aggregation 
[15], inflammatory processes, hypothalamus-pituitary-adrenal axis dysregulation, 
and polyunsaturated fatty acids [16]. Another possible mechanism through which 
depression might increase the risk of adverse cardiac prognosis is decreased heart 
rate variability [17]. Interestingly, it has been indicated that in patients with 
coronary artery disease, somatic depressive symptoms were associated with lower 
heart rate variability, while cognitive depressive symptoms were not [18]. Future 
research should focus on the possibility that there may be specific relations 
between the somatic dimension of depression and certain physiological or 
behavioral mechanisms, rather than with general depression [16]. 
Somatic depressive symptoms might be physical manifestations of more severe 
heart disease and therefore be related to adverse outcome. Although the 
relationship between somatic/affective depressive symptoms and mortality 
remained after controlling for Killip class and history of MI, many factors may 
play a prognostic role in cardiac prognosis and our ability to characterize baseline 
disease severity was limited. For example, we did not have information on LVEF, 
but a meta-analysis showed that adjustment for LVEF reduced risk estimates of 
depression on cardiac outcomes considerably [4]. Therefore we cannot rule out the 
possible confounding role of disease severity in the relation between 
somatic/affective depressive symptoms and mortality. In terms of measuring 
depression, a recent study indicated that MI patients did not have higher somatic 
depressive symptom scores than psychiatric outpatients [19], but that there was a 
preponderance of somatic depressive symptoms at low depression score levels in 
both MI patients and psychiatric outpatients, suggesting that the BDI picks up at 
least a small amount of variance related to physical malaise in all samples, 
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regardless of health status. Related to this, an earlier study that used data from only 
the MI patients in the cohort from this study, found that depression  predicted 
mortality when removing potential bias in BDI scores from somatic symptoms 
unrelated to depression [20]. However, these somatic symptoms were also 
positively related to mortality risk, although not statistically significantly, likely 
due to the small number of mortalities [20]. 
A limitation of this study is the relatively small number of outcome events and 
these events were ascertained from different sources of which the accuracy has not 
been demonstrated. In addition, because time to death was not available we could 
not use a survival model in our analyses which may have resulted in some loss of 
statistical power to detect meaningful associations.  Another limitation is that we 
did not use a diagnostic interview to assess depression. It is important to evaluate 
the associations of cognitive/affective and somatic/affective depressive symptoms 
with cardiac outcome in patients with a depressive disorder, particularly since a 
recent study showed that there is a preponderance of somatic depressive symptoms 
at low depression score levels which could be confounded by medical illness [19]. 
Further, although only the adjusted OR for the somatic/affective component was 
significant, the confidence intervals from the two components overlapped, 
indicating that the difference between the two components was not statistically 
significant.  
In summary, this study among ACS patients showed that somatic/affective 
depressive symptoms, but not cognitive/affective symptoms, were associated with 
disease severity and all-cause mortality. The association with adverse outcome 
remained significant after controlling for demographic and clinical variables. 
However, it is uncertain whether these symptoms reflected depression or rather a 
general malaise due to the coronary event. More research is needed to evaluate the 
differential associations of somatic/affective and cognitive/affective depressive 
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Changes in cognitive versus somatic symptoms of 
depression and event-free survival following acute 
myocardial infarction in the Enhancing Recovery in 
Coronary Heart Disease (ENRICHD) study 







Objectives: A secondary analysis was conducted on data from the Enhancing 
Recovery in Coronary Heart Disease (ENRICHD) trial to assess whether changes  
in somatic or cognitive depressive symptoms following acute MI predicted event-
free survival and whether the results differed per treatment arm (cognitive behavior 
therapy or care as usual). Background: Randomized controlled trials focusing on 
the effects of antidepressant treatment in cardiac patients have found modest 
effects on depressive symptoms but not on cardiac outcomes. Method: Patients 
who met depression criteria and completed the 6th month depression assessment 
(n=1,254) were included in this study. Measurements included demographic and 
clinical data and the Beck Depression Inventory at baseline and 6 months. The 
primary endpoint was a composite of recurrent MI and mortality over 2.4 years 
(standard deviation [SD]=0.9 years). Results: Positive changes in somatic 
depressive symptoms (hazard ratio [HR]: 0.95; 95% confidence interval [CI]: 0.92-
0.98; p=0.001) but not in cognitive depressive symptoms (HR: 1.00; 95% CI: 0.97-
1.03; p=0.99) were related to a reduced risk of recurrent MI and mortality after 
adjustment for baseline depression scores. There was a trend for an interaction 
effect between changes in somatic depressive symptoms and the intervention 
(p=0.08). After controlling for demographic and clinical variables, the association 
between changes in somatic depressive symptoms and event-free survival remained 
significant in the intervention arm (HR: 0.93; 95% CI: 0.88-0.98; p=0.01) only. 
Conclusions: Changes in somatic depressive symptoms, and not cognitive 
symptoms, were related to improved outcomes in the intervention arm, independent 
of demographic and clinical variables.  





Depression is associated with morbidity and mortality in patients with coronary 
heart disease (CHD) [1,2]. Randomized controlled trials focusing on the effects of 
antidepressant treatment in cardiac patients have found modest effects on 
depressive symptoms but not on cardiac outcomes [3-5]. Further analyses of these 
studies revealed that patients who did not respond to antidepressant treatment were 
at increased risk of adverse outcomes [6-8]. Several recent studies suggest that 
somatic symptoms of depression (e.g. fatigue, sleep problems), but not cognitive 
symptoms (e.g. shame, guilt) are related to adverse cardiac prognosis in patients 
with myocardial infarction (MI) [9-11]. No previous studies have focused on the 
changes in cognitive and somatic depressive symptoms after depression treatment 
and their potentially differential associations with event-free survival.  
This is a secondary analysis of data from the Enhancing Recovery in Coronary 
Heart Disease (ENRICHD) trial. We assessed whether somatic and cognitive 
depressive symptoms improved after cognitive behavior therapy (CBT) and 
whether changes in somatic or cognitive depressive symptoms following acute MI 
were related to event-free survival. We also assessed whether these associations 
differed by treatment arm since an earlier study based on the ENRICHD trial 
showed that intervention patients whose depression did not improve were at higher 
risk for late mortality than were patients who responded to treatment [7]. We 
hypothesized that positive changes in somatic symptoms of depression are 
associated with a reduced rate of recurrent MI and all-cause mortality.  
Method 
Subjects 
Participants were patients recruited within 28 days following an acute MI who met 
modified DSM-IV criteria for major depressive disorder, minor depressive disorder 
with a history of major depressive disorder, or dysthymia [12]. Patients admitted 
between October 1996 and November 1999 to coronary care units at eight 
ENRICHD clinical trial sites for an MI were screened for eligibility. MI was 
documented by cardiac enzymes and by chest pain compatible with acute MI, 
characteristic evolutionary ST-T changes, or new Q waves. Details of the methods 
and design of the ENRICHD clinical trial are available elsewhere [4,12]. Briefly, 




1. had other life-threatening medical illnesses, cognitive impairment, other 
major psychiatric disorders, or were at imminent risk of suicide; 
2. were too ill or logistically unable to participate; 
3. had been taking a non-study antidepressant for less than 21 days; or 
4. were exempted by their cardiologist from participating in the study. 
For the present analyses, patients included in ENRICHD with low perceived social 
support but no depression were excluded, as were patients who had a recurrent MI 
or died before the assessment of depression outcomes (6 months). 
Assessment 
Depressive symptoms were measured with the Beck Depression Inventory (BDI), a 
21-item self-report measure developed to assess the presence and severity of 
depressive symptoms [13]. Each item is rated on a 0-3 scale with higher scores 
reflecting greater severity. The BDI is a valid and reliable measure of depressive 
symptoms in cardiac patients (14). For the present study, we used the BDI at the 
time of randomization and at 6 months post-randomization to calculate difference 
scores comparable to the time frame of the active treatment arm. Depressive 
symptoms were defined as cognitive or somatic using the original division 
proposed by Beck and Steer [15]. Therefore, the items concerning sadness, 
pessimism, sense of failure, dissatisfaction, guilt, punishment, self-dislike, self-
accusations, suicidal ideas, crying, irritability, social withdrawal, and 
indecisiveness were summed to obtain scores for the cognitive depressive 
dimension and the items concerning body image change, work difficulty, insomnia, 
fatigue, loss of appetite, weight loss, somatic preoccupation, and loss of libido were 
summed to obtain scores for the somatic depressive dimension. Further, significant 
change in somatic depressive symptoms was defined as a standardized effect size 
≥0.5. We assessed whether patients who significantly improved were at decreased 
risk of adverse outcomes and we compared baseline characteristics of patients who 
significantly improved with characteristics of patients who did not improve.  
Design and treatment 
After written informed consent was obtained, the participants were randomly 
assigned by an automated system located at the ENRICHD coordinating center 
within 28 days of their index MI, to receive either the intervention or usual care. 
Both groups received the American Heart Association’s Active PartnershipTM  




health education booklet. The usual care patients received no further contact from 
study personnel except for follow-up.  
The intervention consisted of CBT and was guided by two standard CBT manuals 
[16,17]. The Beck Institute for Cognitive Therapy and Research provided the 
training and quality control for the intervention. The therapists were supervised by 
clinical investigators at each site and by Beck Institute Personnel. The intervention, 
training and quality control procedures are described in detail elsewhere [18]. 
Participants randomized to the intervention arm who were severely depressed 
(Hamilton Rating Scale for Depression score >24) at enrolment or who did not 
show at least a 50% reduction in BDI scores after five weeks of CBT were referred 
to a study psychiatrist for concurrent pharmacotherapy. For these patients, unless 
contraindicated, sertraline was initiated at 50 mg per day. Patients who were unable 
to tolerate or who were unresponsive to sertraline were switched to an alternative 
antidepressant. The maximum duration of treatment was 6 months of CBT and 12 
months of sertraline.  
Endpoints 
The primary endpoint for the present analysis was a composite of all-cause 
mortality and recurrent MI, consistent with the primary endpoint of the ENRICHD 
randomized trial [4]. All-cause mortality was a secondary endpoint. These 
endpoints were ascertained by follow-up assessments (including a medical history, 
physical examination and a resting electrocardiograph) and phone calls, routine 
hospital surveillance, and contacts with the patient’s physician. Since this study 
focused on the effects of changes in depressive symptoms on event-free survival, 
only deaths and MIs that occurred after the assessment of depression outcomes (6 
months) were taken into account, which is consistent with previous studies [7,8]. 
The mean follow-up period was 2.4 years (standard deviation [SD]=0.9 years).  
Statistical analysis 
Discrete and continuous variables were compared with the chi-square test and the 
independent-samples t-test. Changes in somatic and cognitive depressive 
symptoms were calculated by subtracting the 6 month sum scores from the baseline 
sum scores. Effect sizes were calculated with Cohen’s d. Cox regression 
analyses were used to model the covariate-adjusted effect of changes in cognitive 
and somatic depressive symptoms between enrollment and the 6-month follow-up 




change in risk associated with a 1-point increase in the respective depressive 
symptom dimension. Further, we assessed whether there was an interaction effect 
between treatment and changes in somatic or cognitive depressive symptoms 
concerning the endpoints. To control for the possible adverse effects of baseline 
depressive symptoms, the hazard estimates of changes in depressive symptoms 
were adjusted for these baseline scores as is consistent with other studies [7]. 
Multivariable analyses were adjusted for demographic and medical factors that 
predicted mortality and recurrent MI in the ENRICHD trial [19], including age, 
diabetes, renal insufficiency, left ventricular ejection fraction (LVEF), creatinine, 
history of pulmonary disease, history of congestive heart failure (CHF), prior 
transient ischemic attack (TIA) or stroke, coronary artery bypass graft surgery 
(CABG) after index MI, and use of non-angiotensin converting enzyme 
vasodilators. Missing scores on the covariates were imputed using a multiple 
imputation procedure with 50 iterations. SAS software 9.1.3 was used to perform 
the multiple imputation and SPSS version 17.0 and STATA version 8 were used 
for the statistical analyses. All statistical tests were 2-tailed, with p<0.05 denoting 
significance. 
Results 
Eleven patients had a missing baseline measurement on the BDI and 341 patients 
did not complete the 6th month depression assessment, leaving 1254 participants, 
654 in the intervention and 600 in the control group, for further analyses. During 
the follow-up period, which started after the 6th month depression assessment, 179 
patients died or had a recurrent MI. Table 1 shows the demographic and clinical 
characteristics of the sample. 








Intervention 570 (53.0) 84 (46.9) 0.13 
Demographic characteristics    
Age years, mean (SD) 59.0 (12.1) 64.1 (11.7) <.001 
Male gender 575 (53.5) 88 (49.2)  0.28 
Caucasian 727 (67.6) 118 (65.9) 0.65 
Education ≥ 12 years 781 (74.1) 117 (68.0) 0.10 
Medical characteristics    
Hypertension 622 (58.6) 118 (68.2) 0.02 
High cholesterol 623 (62.9) 118 (69.8) 0.08 
Diabetes 320 (30.0) 87 (48.9) <.001 
Renal insufficiency 69 (6.5) 38 (22.0) <.001 
Smoking history 698 (65.6) 119 (67.6) 0.60 
LVEF ≤ 40 191(21.7) 60 (42.0) <.001 
Killip II-III-IV 199 (20.2) 59 (37.3) <.001 
BMI, mean (SD) 29.2 (6.0) 28.1 (5.7)  0.02 
Creatinine (mg/dl), mean (SD) 1.07 (0.6) 1.43 (1.1) <.001 
history of pulmonary disease 180 (16.9) 50 (28.4) <.001 
Prior MI 237 (22.4) 72 (41.9) <.001 
History of CHF 99 (9.7) 44 (27.0) <.001 
prior TIA or stroke 75 (7.1) 31 (17.9)  <.001 
Prior CABG 105 (9.8) 39 (22.2) <.001 
Prior PTCA 144 (13.6) 35 (20.2) 0.02 
Prior peripheral vascular disease 115 (10.9) 40 (23.1) <.001 
Treatment of index MI    
Thrombolytic therapy 398 (37.6) 58 (32.8) 0.22 
CABG 191 (18.2) 28 (16.3) 0.53 
PTCA 547 (51.5) 66 (38.2)  0.001 
Medications    
ACE inhibitors 455 (44.3) 94 (55.6) 0.01 
Vasodilators (non-ACE) 405 (39.7) 83 (49.7) 0.02 
anticoagulants 191 (18.9) 46 (27.4) 0.01 
aspirin 925 (88.4) 141 (82.5) 0.03 
Beta-blockers 793 (76.2) 116 (69.0)  0.05 
Lipid-lowering drugs 469 (45.7) 79 (47.6) 0.65 
Antidepressant medication use at baseline 89 (8.3) 9 (5.0)  0.13 
Antidepressant medication use during follow-up 289 (26.9) 47 (26.3) 0.86 
 
ACE= angiotensin-converting enzyme; BMI= body mass index; CABG= coronary artery bypass graft; CHF= 
congestive heart failure; LVEF= left ventricular ejection fraction; MI= myocardial infarction; PTCA= 
percutaneous transluminal coronary angioplasty; SD= standard deviation; TIA= transient ischemic attack. 
 




Changes in depressive symptoms 
Patients had a mean positive change of 4.00 (SD=6.01) in cognitive depressive 
symptoms and a positive change of 3.33 (SD=4.53) in somatic depressive 
symptoms from baseline to the 6 month follow-up.   
The mean change was significantly larger for the intervention group for both the 
cognitive symptoms (4.71 [SD=6.07] versus 3.24 [SD=5.85]; p<.001) and the 
somatic symptoms, (mean=3.95 [SD=4.43] versus 2.66 [SD=4.54]; p<.001) 
compared to the care as usual group.  
Changes in depressive symptoms as predictors of event-free survival 
Baseline cognitive depressive symptoms (HR: 1.00; 95% confidence interval (CI): 
0.97-1.03; p=0.99) were not related to mortality and recurrent MI at follow-up, 
while baseline somatic depressive symptoms were (HR: 1.05; 95% CI: 1.01-1.09; 
p=0.01). After adjustment for baseline cognitive depressive symptom scores, 
changes in cognitive depressive symptoms were not associated with improved 
outcome (HR: 0.98; 95% CI: 0.96-1.01; p=0.19). However, positive changes in 
somatic depressive symptom scores were significantly related to event-free 
survival after controlling for baseline somatic depressive scores (HR: 0.95; 95% CI: 
0.92-0.98; p=0.001). There was no interaction effect between changes in cognitive 
symptoms and treatment arm (p=0.25) but there was a trend for an interaction 
effect between changes in somatic depressive symptoms and the intervention 
(p=0.08), indicating that the effect of changes in somatic depressive symptoms on 
prognosis tended to differ by treatment group. We further assessed the association 
between changes in somatic depressive symptoms and adverse outcomes in the two 
treatment groups. After adjustment for demographic and medical covariates, 
change in somatic depressive symptoms was not related to prognosis in the control 
group (HR: 1.00; 95% CI: 0.95-1.05; p=0.96), but was an independent predictor of 
event-free survival in the intervention group (HR: 0.93; 95% CI: 0.88-0.98; p=0.01) 
(table 2). Because antidepressant use differed between the intervention and control 
group, we additionally adjusted for use of selective serotonin reuptake inhibitors, 
but this did not change the association between changes in somatic depressive 
symptoms and event-free survival in the intervention group (HR: 0.92; 95% CI: 
0.87-0.97; p=0.004).  
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Table 2: Association between positive changes in somatic depressive symptoms 
and mortality and recurrent MI in the intervention group 
Predictor variables HR 95% CI p 
Changes in somatic depressive symptoms 0.93 0.88-0.98 0.01 
Baseline somatic depressive symptoms 1.04 0.98-1.11 0.19 
Age 1.03 1.01-1.05 0.001 
Diabetes 1.48 0.93-2.35 0.10 
Renal insufficiency 1.49 0.75-2.96 0.25 
LVEF % 0.98 0.96-1.00 0.04 
Creatinine 1.33 1.07-1.65 0.01 
History of pulmonary disease 1.81 1.09-2.99 0.02 
Prior MI 1.44 0.89-2.32 0.13 
History of CHF 1.30 0.74-2.31 0.36 
Prior TIA or stroke 1.06 0.53-2.15 0.87 
CABG treatment of index MI 1.00 0.53-1.88 0.99 
Use of vasodilators (non-ACE) 0.97 0.59-1.59 0.90 
 
ACE= angiotensin-converting enzyme; CABG= coronary artery bypass graft; CHF= congestive heart failure; 
LVEF= left ventricular ejection fraction; MI= myocardial infarction; TIA= transient ischemic attack. 
 
 
We found similar results with respect to the secondary endpoint, all-cause mortality. 
There was a significant interaction effect between changes in somatic depressive 
symptoms and the intervention concerning the secondary endpoint (p=0.02). 
Change in somatic depressive symptoms was an independent predictor of all-cause 
mortality in the intervention group (HR: 0.91; 95% CI: 0.85-0.97; p=0.004) but not 
in the care as usual group (HR: 1.02; 95% CI: 0.96-1.08; p=0.55) after adjustment 
for baseline somatic depressive symptoms scores, and demographic and medical 
covariates. 
Patients whose somatic depressive symptom scores improved substantially 
(standardized effect size ≥0.5) after CBT (standardized effect size ≥0.5) were at 
decreased risk of adverse outcomes compared with patients who did not improve. 
Although this association was not significant for the primary endpoint (HR: 0.70; 
95% CI: 0.44-1.09; p=0.11), it was significant for the secondary endpoint (HR: 
0.52; 95% CI: 0.29-0.94; p=0.03) (figure 1). The association between improvement 
in somatic depressive symptoms and all-cause mortality in the intervention group 
remained marginally significant after adjustment for demographic and medical 





Figure 1: Improvement in somatic depressive symptoms following treatment and 
association with survival. 
 




Comparison of demographic and medical characteristics between groups 
Demographic and medical characteristics of patients whose somatic depressive 
symptom scores improved after CBT were compared with patients whose somatic 
symptoms did not improve during treatment. Patients who did not improve were 
more likely to be treated with antidepressants during the intervention (p<.001), 
which is explained by the design of the intervention, as only patients who were 
severely depressed at baseline or who did not respond quickly enough to the CBT 
received antidepressant medication. Further, patients who improved during the 
intervention were more likely to be female (p=0.01). Finally, patients who did not 
improve during treatment were more likely to have a history of transient ischemic 
attack (TIA) or stroke (p=0.05) and to have high cholesterol (p=0.05) (table 3) than 
those whose somatic depressive symptoms improved. 












Demographic characteristics    
Age years, mean (SD) 59 (12.1) 59 (12.4) 0.98 
Male gender 115 (63.2) 241 (51.1) 0.01 
Caucasian 130 (71.4) 318 (67.4) 0.32 
Education ≥ 12 years 139 (77.7) 340 (73.1) 0.24 
Medical characteristics    
Hypertension 112 (62.2) 270 (58.1) 0.34 
High cholesterol 116 (69.9) 268 (61.3) 0.05 
Diabetes 56 (30.9) 146 (31.0) 0.99 
Renal insufficiency 18 (10.2) 37 (8.0) 0.38 
Smoking history 120 (66.7) 302 (64.7) 0.63 
LVEF <40 35 (23.2) 95 (23.9) 0.87 
Killip II-III-IV 36 (22.6) 101 (23.1) 0.90 
BMI, mean (SD)  29.3 (5.5) 28.7 (5.8) 0.26 
Creatinine (mg/dl), mean (SD) 1.2 (0.8) 1.1  (0.7) 0.23 
history of pulmonary disease 34 (19.0) 85 (18.1) 0.80 
Prior MI 47 (26.3) 103 (22.3) 0.29 
History of CHF 24 (13.8) 51 (11.4) 0.41 
prior TIA or stroke 19 (10.6) 28 (6.0) 0.05 
Prior CABG 22 (12.2) 48 (10.2) 0.48 
Prior PTCA 31 (17.2) 59 (12.6) 0.13 
Prior peripheral vascular disease 28 (15.9) 54 (11.6) 0.14 
Treatment of index MI    
Thrombolytic therapy 53 (29.6) 173 (37.0) 0.08 
CABG 22 (12.3) 83 (18.0) 0.08 
PTCA 91 (50.0) 225 (48.4) 0.71 
Medications    
ACE inhibitors 76 (42.7) 190 (41.9) 0.86 
Vasodilators (non-ACE) 74 (42.0) 181 (40.6) 0.74 
anticoagulants 28 (15.8) 100 (22.5) 0.06 
aspirin 155 (88.1) 396 (86.3) 0.55 
Beta-blockers 137 (76.5) 346 (76.4) 0.97 
Lipid-lowering drugs 85 (48.6) 194 (43.0) 0.21 
Antidepressant medication use at baseline 25 (13.7) 41 (8.7) 0.06 
Antidepressant medication use during follow-up 74 (40.7) 127 (26.9) <.001 
 
ACE= angiotensin-converting enzyme; BMI= body mass index; CABG= coronary artery bypass graft; CHF= 
congestive heart failure; LVEF= left ventricular ejection fraction; MI= myocardial infarction; PTCA= 
percutaneous transluminal coronary angioplasty; SD= standard deviation; TIA= transient ischemic attack.  
 





This study is the first to assess changes in somatic and cognitive depressive 
symptoms after depression treatment and their association with event-free survival 
in depressed MI patients. Patients who received antidepressant treatment, namely 
CBT and concurrent antidepressant medication when necessary, had larger changes 
in cognitive and somatic depressive symptoms compared with patients in the usual 
care group. Changes in cognitive depressive symptoms were not related to event-
free survival. Conversely, changes in somatic depressive symptoms were related to 
improved outcomes in the intervention group, independent of demographic and 
clinical variables, including disease severity and use of selective serotonin reuptake 
inhibitors. This association was not apparent for the control group.  
Earlier studies found that somatic depressive symptoms and not cognitive 
depressive symptoms were associated with adverse outcomes in patients following 
an acute MI [9-11] or acute coronary syndrome [20], although not consistently [21]. 
Somatic depressive symptoms were also more strongly associated with adverse 
outcomes in patients with myocardial ischemia [22], heart failure [23], and stable 
CHD [24], although a study in patients treated with CABG surgery found that 
cognitive depressive symptoms were predictive of cardiac mortality and somatic 
depressive symptoms were not [25]. The results of the current study add to our 
understanding of the effects of somatic versus cognitive depressive symptoms in 
MI patients and suggest that trials aiming to improve cardiac prognosis in 
depressed MI patients should pay close attention to the somatic depressive 
symptoms since improvements in somatic depressive symptoms may play an 
important role in improving cardiac prognosis. 
There may be several reasons why changes in somatic depressive symptoms were 
associated with improved outcomes in the treatment group only. First, the 
association between changes in somatic depressive symptoms with event-free 
survival might be caused by specific effects of the therapy. A second explanation is 
that the association between changes in somatic depressive symptoms with event-
free survival is the result of the presence of a subtype of depression which does not 
respond to treatment with CBT and concurrent antidepressant medication [7,8,26]. 
This subtype might be characterized by persistent somatic depressive symptoms 
associated with a high risk for mortality. A recent secondary analysis of the 
ENRICHD clinical trial data showed that somatic depressive symptoms at 12 
months post-MI predicted mortality, while baseline somatic depressive symptoms 
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did not [27]. Also, a recent study showed that residual symptoms after depression 
treatment were more often somatic, namely lack of energy and sleeping problems 
[28] suggesting that persistent somatic depressive symptoms might be an indication 
of recurrent or chronic depression. Therefore, in this study, it is possible that the 
intervention identified patients with a high risk subtype of depression unresponsive 
to standard antidepressant treatment [26]. How this subgroup can be further 
specified remains unclear, although there are several propositions. First, patients 
who do not respond to antidepressant medication are more likely to have elevated 
levels of inflammation [29]. Since inflammatory processes have been associated 
with recurrent cardiac events [30], inflammation is a potential mechanism linking 
poor treatment response to standard antidepressant treatment with adverse cardiac 
outcomes [26]. Another factor related to non-response to antidepressant treatment 
is obstructive sleep apnea.  A study with patients with CHD found that patients 
with comorbid sleep apnea were less likely to respond to antidepressant medication 
as compared to patients without sleep apnea [31]. Treatment resistant depression 
may be a marker of underlying sleep apnea [31] which is a risk factor for MI and 
sudden cardiac death in patients with CHD [32].  
This study has several clinical implications. First, close monitoring of changes in 
somatic depressive symptoms might help to improve clinical care for patients with 
MI. If patients do not respond to antidepressant treatment with significantly 
improved somatic symptoms, additional treatments may be considered, even if 
overall depression severity improves. Also, specific cardiac risk factors that predict 
treatment resistance to antidepressant therapy in patients with CHD, e.g. sleep 
apnea, should be identified and treated, potentially leading to better cardiovascular 
outcomes. Further, depression treatments that also modify cardiac risk markers in 
patients with CHD might lead to better depression and medical outcomes [26]. For 
example, exercise therapy may offer considerable promise in patients with heart 
disease through a decrease in depressive symptoms and by simultaneously 
modifying mechanisms by which depression may be associated with increased risk, 
including autonomic nervous system and hypothalamic pituitary-adrenal axis 
dysfunction, and increased platelet activation and inflammation [33].  
Somatic depressive symptoms might be physical manifestations of more severe 
heart disease and therefore be related to adverse outcomes. However, the 
association between changes in somatic depressive symptoms with event-free 
survival remained significant after adjustment for established predictors of 




comorbid diseases. Also, patients whose somatic depressive symptoms did not 
improve did not significantly differ on demographic and clinical cardiac risk 
factors compared with patients whose depressive symptoms improved, other than 
that patients who did not improve were more likely to be male and have high 
cholesterol levels. Nevertheless, although affecting only a small group of patients, 
those whose somatic depressive symptoms did not improve appeared to be more 
likely to have had a TIA or stroke in the past, supporting the vascular depression 
hypothesis which suggests that cerebrovascular disease can induce depressive 
symptoms [34]. Therefore, we cannot exclude the possibility of underlying 
pathophysiology explaining at least part of the relationship between somatic 
depressive symptoms and outcomes.  
A limitation of this study is that we did not take into account the possible effects of 
a worsening of cardiac disease during the six months of depression treatment. 
However, to minimize this possibility we excluded patients who had a recurrent MI 
during the time frame of the active treatment arm from our analyses. As a second 
limitation, there were a considerable number of patients who did not complete the 
6th month depression assessment. Further, we defined depressive symptoms as 
either cognitive or somatic concordant with Beck and Steer [15]. Principal 
component analyses have shown that, although a 2 factor solution is found in most 
cases [10,20,27], the BDI items are often not completely consistent [9,10,20,27]. 
For example, a recent study on the ENRICHD trial found that body image change 
loaded on the cognitive dimension instead of the somatic dimension [27]. However, 
excluding body image change from the somatic depressive symptom dimension did 
not change the relationship between changes in somatic depressive symptoms and 
prognosis in this study (data not shown). Finally, since these are secondary, post 
hoc analyses of the ENRICHD trial, the results should be interpreted with caution.  
In summary, we found that positive changes in somatic depressive symptoms, and 
not cognitive depressive symptoms, were related to event-free survival after 
treatment with CBT in depressed patients with MI. This association was 
independent of demographic and clinical variables, including disease severity, and 
was restricted to the intervention arm. 
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Objective: Evidence from several clinical trials in patients with coronary heart 
disease (CHD) suggests that depression that does not respond to treatment is 
associated with a particularly high risk of adverse cardiac outcomes. The purpose 
of this study was to determine whether obstructive sleep apnea/hypopnea (OSAH) 
is associated with a poor response to antidepressant medication in patients with 
CHD. Method: This was an ancillary study of a clinical trial of omega-3 fatty acid 
augmentation of sertraline for depression in patients with CHD. Cyclical heart rate 
(HR) patterns associated with OSAH were detected via ambulatory 
electrocardiography prior to treatment. Symptoms of depression were measured at 
baseline and follow-up with the Beck Depression Inventory-II (BDI-II) and the 
Hamilton Rating Scale for Depression (HAM-D-17). The primary endpoint was the 
BDI-II score at 10 weeks. Results: Thirty (29%) of the 105 patients were classified 
as having moderate to severe OSAH, based on HR patterns. Patients with OSAH 
had significantly higher scores on both the BDI-II (p=0.01) and the HAM-D-17 
(p=0.02) at follow-up as compared to the reference group. Adjustment for the 
baseline depression score, treatment arm (omega-3 versus placebo), body mass 
index, and inflammatory markers did not change the results. Conclusion: OSAH is 
associated with a relatively poor response to sertraline for depression. Future 
research should determine the contribution of OSAH to the increased risk of 
adverse cardiac outcome associated with treatment resistant depression.  
Clinical Trial Registration: NCT00116857, www.clinicaltrials.gov. 




Depression is associated with morbidity and mortality in patients with coronary 
heart disease (CHD) [1,2]. Randomized controlled trials focusing on the effects of 
antidepressant treatment on depression and cardiac outcome have found modest 
effects on depressive symptoms but no effect on cardiac outcome [3,4]. Secondary 
analyses of these studies have shown that patients who did not respond to the 
antidepressant treatment were at increased risk of adverse cardiac events [5,6]. 
Therefore, depression that does not respond to treatment may be associated with a 
particularly high risk of mortality or cardiac morbidity in patients with CHD [7]. 
There are no well established risk factors for nonresponse to antidepressant 
treatment in CHD patients [6,7]. Obstructive sleep apnea hypopnea (OSAH) has 
been linked to treatment-resistant depression in depressed psychiatric patients [8-
10]. However, this has not yet been investigated in patients with CHD.  
OSAH is a chronic, sleep-related breathing disorder characterized by recurrent, 
complete (apnea) or partial (hypopnea) blockage of the upper airway. OSAH is a 
potent trigger of nocturnal myocardial ischemia and dysrhythmias characteristic of 
cardiac sympathetic predominance, and it is associated with low heart rate 
variability (HRV). Consequently, OSAH is a significant risk factor for acute 
myocardial infarction (MI) and sudden cardiac death in patients with CHD [11-14]. 
OSAH is common in patients with CHD, with an estimated prevalence of 30-50% 
[15-17]. Despite the high prevalence and associated risk for cardiac events, OSAH 
is seldom identified or treated in these patients [18].   
OSAH is usually diagnosed by polysomnography at a sleep medicine laboratory. 
However, Guilleminault et al [19] observed that OSAH can also be identified from 
a cyclical heart rate (HR) pattern that begins with a slowing in HR, sometimes 
leading to bradycardia, shortly after the onset of the apneic episode. HR then shifts 
abruptly to tachycardia with the resumption of breathing, and concludes with a 
return to baseline if there is a sufficiently long interval of normal breathing after 
the apneic episode [19]. Previous studies have reported a correlation of r=0.96 
between the frequency of apneic events associated with an O2 desaturation of >3% 
during polysomnography, and the frequency of this HR pattern on simultaneous 
electrocardiography (ECG) [20]. The characteristic pattern can be detected in 
ambulatory ECG data, and has been shown to be a highly sensitive and specific test, 




The purpose of this study was to test the hypothesis that the presence of OSAH, as 
identified from the cyclical HR pattern, is associated with a poor response to 
antidepressant treatment.  
Method 
Subjects and study design 
This question was examined in data collected for a randomized, double blinded, 
placebo-controlled clinical trial of omega-3 augmentation of sertraline for 
depression in patients with CHD. The trial found no effects of omega-3 
augmentation on depression outcomes [22]. Patients with documented CHD were 
recruited between May, 2005 and December, 2008 from cardiology practices in St. 
Louis, MO, and from cardiac diagnostic laboratories affiliated with Washington 
University School of Medicine. Patients were excluded if they 1) had cognitive 
impairment, comorbid psychiatric disorders, psychosis, a high risk of suicide, or 
current substance abuse; 2) had an acute coronary syndrome (ACS) within the 
previous two months, a left ventricular ejection fraction (LVEF) <30%, advanced 
malignancy, or were physically unable to participate; 3) were taking an 
antidepressant, anticonvulsant, lithium, or omega-3 supplements; 4) had a known 
sensitivity to sertraline or omega-3; or 5) refused to participate or were disqualified 
by their physician from participating in the study. Those who met the Diagnostic 
and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV) criteria for 
a current major depressive episode based on a structured depression interview [23], 
who scored ≥16 on the Beck Depression Inventory (BDI-II) [24], and who met 
none of the exclusion criteria, were enrolled in the trial. Written informed consent 
was obtained from all study participants. The study was approved by the Human 
Research Protection Office at Washington University. 
 After a two week run-in phase, patients who continued to meet the depression 
criteria and who were not excluded for other reasons were fitted with an 
ambulatory ECG monitor for a 24 hour recording. Following baseline assessments, 
patients were randomized to receive 50 mg per day of sertraline plus either two 
capsules per day of omega-3 fatty acid (FA) ethyl esters [930 mg of 
eicosapentaenoic acid (EPA) and 750 mg of docosahexaenoic acid (DHA)] or two 
corn oil placebo capsules, for 10 weeks. Compliance with both the sertraline and 
the omega-3 or placebo capsules was checked weekly by pill counts, and by asking 
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the participant to confirm that all pills that had been removed were actually taken 
as prescribed.   
At baseline and 10 weeks, 40 ml of blood was drawn. Red blood cell (RBC) 
membrane EPA+DHA was measured pre- and post-treatment by capillary gas 
chromatography and expressed as a percentage of the total RBC FAs (i.e., the 
omega-3 index) [25]. High sensitivity C-reactive protein (hs-CRP) and interleukin 
6 (IL-6) were measured by standard techniques. Further details on the design and 
methods of this study can be found elsewhere [22]. 
Ambulatory ECG Recording 
The Holter ECG recordings were scanned at the Heart Rate Variability Core 
Laboratory at Washington University with Cardioscan Holter (Version 52a, DMS 
Holter, Stateside, NV) or MARS Holter scanning software (Version 7.01, GE 
Medical Systems, Milwaukee, WI). A continuous stream of instantaneous, 
accurately annotated (beat-to-beat) interbeat intervals was extracted from the ECG 
and HR tachograms (plots of instantaneous heart rate vs. time) were produced. 
Only validated normal-to-normal interbeat intervals were used to produce the 
tachograms. The cyclical HR pattern criteria required a series of at least 3 abrupt 
tachycardias, each lasting >10 seconds, followed by a return to baseline and 
occurring >30 and <90 seconds apart [20]. his pattern was identified by applying 
the algorithm developed at the Washington University School of Medicine [20]. In 
a recent study using this method, the presence of these HR patterns had a 
sensitivity of 98% and a positive predictive value of >92% for identifying patients 
with moderate to severe OSAH, defined as >30 episodes of apneas and/or 
hypopneas per hour of sleep as determined from polysomnography [26]. Patients 
with at least two consecutive hours of the cyclic variation of HR pattern during 
sleep were classified as having OSAH. These classifications were confirmed by 
visual inspection.   
Assessment of depressive symptoms 
Symptoms of depression were measured at baseline and follow-up with the BDI-II 
and the Hamilton Rating Scale for Depression (HAM-D-17). The BDI-II is a 21-
item depression symptom questionnaire with scores ranging from 0 to 63. The 17-
item HAM-D-17 is an interview-based measure of depression symptom severity. 
Both are widely used for assessing depression outcomes and have established 




weeks, consistent with the primary outcome of the clinical trial [22]. The HAM-D 
score at 10 weeks was used as a secondary outcome.  
Statistical analysis 
Chi-square tests and analyses of variance (ANOVA) were used to test for 
differences in demographic, psychiatric, and medical characteristics, and in 
treatment adherence between patients with vs. without OSAH. Analysis of 
covariance (ANCOVA) models adjusting for baseline depression scores and 
treatment assignment (omega-3 augmentation or placebo) were used to compare 
patients with vs. without OSAH on week 10 BDI-II and HAM-D scores. The 
interaction between OSAH and treatment assignment was tested to determine 
whether the hypothesized effect of OSAH on the response to sertraline depends on 
the presence or absence of omega-3 augmentation. In additional secondary 
ANCOVA models, we tested the possible confounding effects of body mass index 
(BMI), hs-CRP, and IL-6, as obesity and inflammation have been associated with 
poor treatment response to antidepressant treatment [29,30]. Cohen’s d was 
calculated for the OSAH vs non-OSAH group difference in BDI-II scores at 
follow-up. To explore whether the difference in depression outcome might be 
explained by nonspecific symptoms such as fatigue, ANOVA was used to identify 
differences in individual depressive symptoms at 10 weeks on the BDI-II in 
patients with vs. without OSAH. All statistical tests were 2-tailed, with p<.05 
denoting significance. SAS version 9.1 was used for all statistical analyses.  
Results 
Of the 122 patients enrolled and randomized in the clinical trial, 12 did not undergo 
24 hour Holter monitoring because they had a pacemaker and one could not be 
monitored due to a history of allergic reaction to the ECG lead adhesive. Of those 
who underwent monitoring, HR could not be measured in 4 patients due to 
equipment failures. Thus, 105 had usable ECG data at baseline (Figure 1).  
Figure 1: Study Flow Chart 







Consistent with the findings of previous studies of patients with CHD [15,16], the 
prevalence of OSAH was high in this sample. Thirty (29%) of the 105 patients 
were classified as having OSAH, based on HR patterns during self-reported sleep. 
Table 1 compares the demographic and medical characteristics of the patients with 
vs. without OSAH. Patients with OSAH had higher BMIs and higher hs-CRP 
levels than those without OSAH. There were no differences in the severity or 
duration of the present depressive episode, history of depression, or history of 
depression treatment.  
Table 1: Baseline demographic and medical characteristics 
OSAH= obstructive sleep apnea hypopnea; BMI= body mass index; MI= myocardial infarction; ACS= acute 
coronary syndrome; CABG= coronary artery bypass graft; PTCA= percutaneous transluminal coronary 
angioplasty; CHF= chronic heart failure; HDL= high-density lipoprotein; hs-CRP= high-sensitivity C-reactive 
protein; IL-6= Interleukin-6. 
 
 
Characteristic Obstructive Sleep Apnea/Hypopnea p 
 Present (n=30) Absent (n=75)  
 n % n %  
Treatment assignment (Omega 3) 17 56.7 37 49.3 0.50 
Age, mean (SD) 58.7 9.9 58.4 8.8 0.89 
Female  8 26.7 28 37.3 0.30 
White 22 73.3 65 86.7 0.10 
Education > 12 years 20 66.7 48 64.0 0.80 
BMI, mean (SD) 37.0 9.3 31.6 5.8 <.001 
Smoking  9 30.0 15 20.0 0.27 
Hypertension 24 80.0 57 76.0 0.66 
Diabetes 13 43.3 26 34.7 0.41 
History of MI/ACS 17 56.7 44 58.7 0.85 
History of CABG 14 46.7 22 29.3 0.09 
History of PTCA 17 56.7 49 65.3 0.41 
New York Heart Association class     0.24  
No CHF 17 56.7 51 68.0  
I 3 10.0 7 9.3  
II 6 20.0 15 20.0  
III 3 10 1 1.3  
IV 1 3.3 1 1.3  
Total cholesterol (mg/dL), mean (SD) 173.3 42.8 170.4 42.9 0.76 
HDL cholesterol (mg/dL), mean (SD) 43.3 16.1 44.6 12.6 0.69 
Triglycerides, fasting (mg/dL), mean (SD) 205.6 159.7 174.4 104.8 0.25 
hs-CRP (mg/L), mean (SD) 7.8 7.3 5.0 5.8 0.04 
IL-6 (pg/ml), mean (SD) 3.9 3.1 3.0 2.4 0.12 
Medication use      
Aspirin 21 70.0 63 84.0 0.11 
Calcium channel blockers 12 40.0 22 29.3 0.29 
 Beta blockers 22 73.3 61 81.3 0.36 
Ace inhibitors 17 56.7 34 45.3 0.29 
Statins 20 66.7 59 78.7 0.20 
Depression characteristics      
 History of major depression 20 66.7 48 67.6 0.93 
Duration of current depressive episode 
(months) 
13.7 18.4 13.4 17.1 0.93 
History of depression treatment 19 63.3 46 61.3 0.85 
Heart Rate (daytime)      
Very Low Frequency (natural logarithm) 
mean, (SD) 
6.90 .73 6.70 .91 0.34 





Post-treatment (10 week) outcomes  
Four participants did not complete the post-treatment depression assessment. As 
shown in Table 2, treatment adherence did not differ between patients with and 
without OSAH.  After 10 weeks of treatment, patients with OSAH had a mean 
score of 19.0 (sd=11.0) on the BDI-II. The mean score of the comparison group 
was 13.0 (sd=9.2). Patients with OSAH had significantly higher BDI-II (t=-2.78; 
p= .01) and HAM-D (t=-2.33; p=.02) scores compared to patients without OSAH. 
These results remained significant for both the BDI-II (t=-2.49; p=.01) and the 
HAM-D (t=-2.03; p=.04) after controlling for the baseline depression score and 
treatment group (omega-3 or placebo). The interaction between OSAH and 
treatment group provided no evidence that the association between depression and 
OSAH differed by group at follow up: BDI-II (F=3.30; p=0.07) and HAM-D 
(F=0.09; p=.77). Further adjustment for BMI, hs-CRP, and IL-6 did not affect the 
association between OSAH and treatment response to sertraline (Table 2).The 
standardized effect (Cohen’s d) of OSAH was 0.62 for the BDI-II follow-up score 
after controlling for baseline depression, treatment group, BMI and hs-CRP.  





Measure Obstructive Sleep Apnea/Hypopnea P 
 Present (n=30) Absenta (n=71)  
 Mean SD Mean SD  
Beck Depression Inventory II      
 Baseline score 30.0 9.0 28.2 9.0 0.35 
 Follow-up score 19.0 11.0 13.0 9.2 0.01 
Adjusted for baseline 18.4 9.1 13.3 9.1 0.01 
Adjusted for baseline, treatment group 18.3 9.2 13.3 9.1 0.01 
Adjusted for baseline, treatment group, BMI2 19.0 9.4 13.2 9.2 0.01 
Adjusted for baseline, treatment group, BMI, hs-CRP3 19.5 9.3 13.8 9.1 0.01 
Adjusted for baseline, treatment group, BMI, IL-64 19.3 9.2 13.2 9.0 0.01 
Hamilton Rating Scale for Depression      
Baseline score 21.2 6.7 20.0 4.8 0.30 
Follow-up score 11.6 7.4 8.4 5.8 0.02 
Adjusted for baseline  11.3 5.9 8.6 5.9 0.04 
Adjusted for baseline, treatment group 11.3 6.0 8.6 6.0 0.04 
Adjusted for baseline, treatment group, BMIb 11.7 6.2 8.5 6.1 0.03 
Adjusted for baseline, treatment group, BMI, hs-CRPc 12.0 6.2 9.1 6.1 0.04 
Adjusted for baseline, treatment group, BMI, IL-6d 11.9 6.2 8.6 6.1 0.02 
Omega-Index (% EPA + DHA in RBC)      
Baseline score 4.8 1.5 4.6 1.5 0.46 
 Follow-up score 6.5 2.2 5.9 2.1 0.26 
Cumulative Treatment Adherence (% days pill 
removed) 
     
Omega-3/Placebo 96.7 5.4 97.8 2.8 0.20 
Sertraline 98.5 2.6 98.9 2.2 0.50 
 
BMI= body mass index; OSAH= obstructive sleep apnea hypopnea; hs-CRP= high-sensitivity C-reactive protein; 
IL-6= Interleukin-6; EPA= eicosapentaenoic acid; DHA= docosahexaenoic acid; RBC= red blood cells. 
 
a = Four participants without OSAH were lost to follow up  
b = BMI was missing for 1 participant 
c = hs-CRP was missing for 7 participants 
d= IL-6 was missing for 1 participant 
 
 
Individual depressive symptoms 
Compared to patients without OSAH, those with OSAH reported higher item 
scores on all depressive symptoms measured at follow-up with the BDI-II. The 
difference was significant for appetite disturbance (p=.002), decreased appetite 
(p=.04), irritability (p=.01), crying (p=.048), agitation (p=.01), sleep disturbance 
(p=.03), insomnia (p=.02), feelings of past failure (p=.04), guilt (p=.03), self-





The results of the study show that moderate to severe OSAH, based on HR patterns 
during sleep, is associated with poor treatment response to sertraline in depressed 
patients with CHD. After 10 weeks, the mean score on the BDI-II was 6 points 
higher for patients with OSAH compared to patients without OSAH. This 
difference could not be attributed to a difference in treatment adherence. The 
association between OSAH and treatment response to sertraline remained 
significant after adjustment for baseline depression severity and treatment group. In 
addition, BMI and inflammatory markers did not account for the relationship 
between OSAH and treatment response. The patients with OSAH reported 
significantly higher scores on a variety of depressive symptoms at follow-up, 
including symptoms not directly related to OSAH, such as self-dislike, feelings of 
past failure, guilt, and worthlessness. Thus, the difference in depression outcome 
was not explained solely by symptoms also associated with OSAH, such as sleep 
problems or fatigue. 
This study raises the possibility that resistance to antidepressant medication might 
be caused in some cases by undiagnosed OSAH. Because OSAH is an independent 
risk factor for cardiac mortality and morbidity, this could help to explain the 
adverse cardiovascular outcomes that have been associated in previous studies with 
treatment-resistant depression. However, OSAH is also a risk factor for depression 
[31], and OSAH and depression might interact to further increase the risk for 
cardiac events. There are multiple possible pathways through which depression 
may lead to adverse outcomes in patients with OSAH. There is evidence that 
depression is associated with a diminished hypercapnic ventilatory response 
[32,34]. In patients with OSAH and comorbid depression, this could prolong apneic 
episodes and produce greater O2 desaturation, and thereby increase the risk for 
cardiac events. Consistent with this possibility, we recently found that depression is 
associated with prolonged episodes of apnea in patients with OSAH [35]. Further 
research is needed to confirm these findings. Additional physiological mechanisms 
associated with both OSAH and depression which could lead to more adverse 
cardiac outcomes include low HRV [36], inflammatory processes, endothelial 
dysfunction, oxidative stress, platelet aggregation, and metabolic dysfunction 
[14,18,37,38]. 
Although OSAH is a common risk factor for further morbidity and mortality in 
patients with heart disease, it is seldom diagnosed or treated [18]. A recent review 





concluded that patients with cardiovascular disease should be routinely screened 
for OSAH [18]. Although polysomnography is the gold standard for diagnosing 
OSAH, validated questionnaires and nighttime ECG patterns can be used to screen 
for the disorder [14]. OSAH can be effectively treated by continuous positive 
airway pressure (CPAP), which prevents upper airway occlusion during sleep [39]. 
CPAP has also been shown to lower blood pressure, attenuate signs of early 
atherosclerosis and, in patients with heart failure, improve cardiac function [40]. 
Since depression that does not respond to standard antidepressant treatment may be 
associated with a particularly high risk of adverse medical outcomes in patients 
with heart disease [7], OSAH is a factor that should be taken into account in future 
depression treatment trials.  
This study has some limitations. First, we assessed the presence of OSAH with 
ECG recordings, although polysomnography is the gold standard for diagnosing 
OSAH. However, nighttime ECG patterns can be used to screen for the disorder 
[14] and previous research has shown that the ECG pattern detected in this study is 
a reliable and valid method for detecting moderate to severe OSAH [20]. In 
addition, patients diagnosed with OSAH by the HR pattern had higher BMIs and 
higher hs-CRP levels than those without OSAH, both of which are associated with 
OSAH. Since the cyclical patterns of HR are most prominent in patients with 
moderate to severe OSAH, it is possible that patients with mild but clinically 
significant OSAH were not recognized. Moderate to severe OSAH is consistent 
with an apnea-hypopnea index (AHI); number of apneas and hypopneas per hour of 
sleep >30, but results from the Sleep Heart Health Study suggest that even an AHI 
as low as 5 is associated with an increased risk of cardiovascular events [41].   
The study also had a relatively small sample size. However, similar to prior studies 
of patients with CHD, the prevalence of previously undetected OSAH was high in 
this group of patients. Furthermore, this study was based on a secondary analysis of 
a randomized controlled trial to the effect of omega-3 augmentation of sertraline 
for the treatment of depression in patients with CHD. The participants were treated 
with a single antidepressant medication at a relatively modest dose. Better 
outcomes might have been achieved if the participants had been given a higher 
dose of sertraline or another antidepressant. However, previous studies have found 
little additional improvement in response rates with higher dosages of sertraline 
(100-200 mg/d), despite a significant increase in side-effects [42,43]. Future 




standard antidepressant medications using additional antidepressants and formal 
definitions of treatment resistance [44].  
In summary, this study showed that OSAH is associated with poor treatment 
response to sertraline in patients with CHD. This association is not explained by 
differences in BMI, hs-CRP, or IL-6, or by nonspecific symptoms common to both 
OSAH and depression. Future research should determine the contribution of OSAH 
to the increased risks associated with depression and investigate whether OSAH 
explains part of the relationship between treatment-resistant depression and cardiac 
outcomes. Additionally, studies are needed to identify better treatments for 
depression in the presence of OSAH, especially in patients with heart disease. 
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Summary and general discussion 
This thesis examined the relationship between anxiety and depression with 
coronary heart disease (CHD). To assess the relationship between anxiety and 
CHD we conducted two meta-analyses, one on the association of anxiety with 
incident CHD and one on the association of anxiety with mortality and new cardiac 
events following acute myocardial infarction (MI). Further, data from two 
observational studies were used to answer questions concerning the association of 
generalized anxiety disorder (GAD) or depressive symptoms with impaired 
prognosis in patients with CHD. In addition, data from two randomized controlled 
trials were used to gain more insight in the relationship between treatment response 
to antidepressant treatment and cardiac outcome.  
The link between anxiety and development and progression of CHD 
The first aim of this thesis was to gain attention to anxiety as a potential risk factor 
for the development and progression of CHD.  
Chapter 2 reported on a meta-analysis focusing on the impact of anxiety on the 
development of CHD in initially healthy individuals. The aim of this study was to 
investigate the association of symptoms of anxiety with incident CHD independent 
of traditional cardiovascular risk factors. This study, including 20 studies sampling 
249.846 persons, showed that anxious persons were at a 26% increased risk of 
CHD and a 48% increased risk of cardiac death, independent of demographic 
variables, biological risk factors and health behaviors. Therefore, anxiety appeared 
to be an independent risk factor for the incidence of CHD and cardiac mortality in 
initially healthy individuals.  
Chapter 3 reported the results of a second meta-analysis, assessing the prognostic 
association of anxiety symptoms in patients with acute MI with impaired prognosis. 
This study included 12 articles and 5.750 MI patients. Results of this study showed 
that post-MI anxiety was consistently related to all-cause mortality, cardiac 
mortality and cardiac events, and anxious patients were at a 36% increased risk of 
adverse outcomes in bivariate analyses. However, more research is needed to 
assess the extent to which this association is independent from other psychological 
and clinical variables.  
Chapter 4 included the results of a study which examined the association of GAD 




evaluate the prognostic association of GAD after MI, measured with the Composite 
International Diagnostic Interview (CIDI), with new cardiac events and mortality 
up till 10 years after the index event. Patients with an acute MI included in the 
DepreMI study (n=438) [1] were included in these analyses. The results showed 
that MI patients with GAD were at an almost 2-fold increased risk of cardiac 
events and all-cause mortality compared to patients without GAD and that this 
association was independent from demographic and clinical variables and 
depression.  
Overall, the results of these studies show that anxiety is associated with an 
increased risk for the development of incident CHD and the progression of CHD in 
patients following acute MI. Furthermore, this association seems to be independent 
from the impact of traditional cardiovascular risk factors and depression. The 
results of these studies indicate the need for future research directed to the 
association between anxiety and CHD and to the identification of possible 
underlying processes. 
The link between depressive symptom dimensions, treatment response, and 
CHD 
Because of the existence of several unresolved issues concerning the relationship 
between depression and CHD, the second aim of this thesis was to provide a deeper 
understanding of the role of depression in CHD. Therefore, the second part of this 
thesis examined several questions concerning the relationship between depression, 
response to depression treatment, and CHD.  
Chapter 5 assessed the differential associations of somatic/affective and 
cognitive/affective depressive symptoms measured with the Beck Depression 
Inventory (BDI) with disease severity and all-cause mortality in 913 patients with 
acute coronary syndrome (ACS). The methods of this study have been described 
previously [2]. This study showed that only somatic/affective depressive symptoms 
were associated with Killip class at baseline. Further, somatic/affective depressive 
symptoms, and not cognitive/affective depressive symptoms, were a predictor of 
all-cause mortality at 12-month follow-up, independent from demographic and 
clinical variables, including disease severity. In addition, the effect of the BDI total 
score on mortality appeared to be completely attributable to the somatic/affective 
symptom dimension.  





In Chapter 6 a secondary analysis was conducted on 1.254 MI patients with 
depression from the ENRICHD trial [3] to assess whether changes in somatic or 
cognitive depressive symptoms following acute MI predicted event-free survival 
and whether the results differed per treatment arm (cognitive behavior therapy 
(CBT) and antidepressant medication when necessary versus care as usual). 
Depressive symptoms were defined as cognitive or somatic using the original 
division proposed by Beck and Steer. The mean improvement during the treatment 
period was larger in the intervention group, both for cognitive and somatic 
depressive symptoms. Positive changes in somatic depressive symptoms but not in 
cognitive depressive symptoms were related to a reduced risk of recurrent MI and 
mortality. An interaction effect was found between changes in somatic depressive 
symptoms and the intervention, meaning that the effect of changes in somatic 
depressive symptoms on prognosis differed by treatment group. After controlling 
for demographic and clinical variables, patients whose somatic depressive 
symptoms improved after CBT had a better prognosis than patients whose somatic 
depressive symptoms did not improve after CBT.  
Since evidence from several clinical trials in patients with CHD suggests that 
depression not responding to treatment is associated with a particularly high risk of 
adverse cardiac outcomes [4-6], the purpose of chapter 7 was to determine whether 
obstructive sleep apnea hypopnea (OSAH), which is a risk factor for adverse 
cardiac events [7], is associated with a poor response to antidepressant medication 
in patients with CHD. This was an ancillary study of a trial of omega-3 fatty acid 
augmentation of sertraline for depression in patients with CHD of which the 
primary results have been presented elsewhere [8]. Thirty (29%) of the 105 patients 
were classified as having moderate to severe OSAH, based on heart rate patterns 
measured with ambulatory electrocardiography. Symptoms of depression were 
measured at baseline and 10-week follow-up with the BDI-II and the Hamilton 
Rating Scale for Depression (HAM-D-17). After adjustment for baseline 
depression scores, treatment arm (omega-3 versus placebo), body mass index, and 
inflammatory markers, OSAH was associated with a poor response to sertraline.  
Overall, the results of these studies give further insight in the relationship between 
depression and CHD. First, somatic depressive symptoms appear to be more 
important predictors of prognosis in patients with ACS compared with cognitive 
depressive symptoms. Nevertheless, we cannot exclude the possibility that the 
relationship between somatic depressive symptoms and adverse cardiac prognosis 




depressive symptoms following CBT are associated with improved prognosis in MI 
patients and these findings suggest that improvements in somatic depressive 
symptoms may play an important role in improving cardiac prognosis in depressed 
patients with MI. Finally, we found that OSAH is related to a poor response to 
antidepressant medication, suggesting that the association between treatment 
resistant depression and adverse cardiac outcomes might be partly explained by 
undiagnosed OSAH. 
Limitations of the present thesis 
One important limitation in conducting meta-analyses is the inevitability of 
combining data from studies with different designs. In both meta-analyses included 
in this thesis, samples from the included studies were heterogeneous regarding 
various study characteristics, including age, gender, follow-up duration, and 
anxiety measurements. This leads to substantial heterogeneity in the results of 
chapter 2. However, the findings of both meta-analyses regarding the association 
between anxiety and incident CHD and impaired prognosis following MI were 
quite consistent across studies. Another limitation is that meta-analyses are prone 
to publication bias. We tried to minimize important sources of publication bias by 
including both non-English and non-published work in our literature searches. 
However, in both meta-analyses we found indications for publication bias, 
suggesting that the associations might be smaller than reported. Another limitation 
of the first part of the thesis is that we only reported on the relationship between 
post-MI GAD with impaired prognosis. Future research should carefully assess the 
relationship between other anxiety disorders (e.g. posttraumatic stress disorder, 
panic disorder, and phobias) and the development and progression of CHD.  
Other limitations of the studies included in the second part of the thesis are that 
confidence intervals for the cognitive and somatic depressive symptom dimensions 
in chapter 5 and 6 overlapped, indicating that the differences between the two 
components were not statistically significant. Further, we did not use a diagnostic 
interview to assess depression in chapter 5. Since there is preponderance of somatic 
depressive symptoms at low depression score levels which could be confounded by 
medical illness [9], it appears relevant to evaluate the associations of cognitive and 
somatic depressive symptoms with cardiac outcomes in patients with a depressive 
disorder. Indeed, a recent analysis showed that somatic depressive symptoms were 
more strongly predictive of cardiovascular events in CHD patients without major 
depressive disorder (MDD) than in CHD patients with MDD, but this association 





was independent from several measures of disease severity [10]. Finally, since 
chapters 6 and 7 were based on secondary analyses of randomized controlled trials, 
the results should be interpreted with caution. Chapter 6 was a secondary, post-hoc, 
analysis of the ENRICHD study which aimed to improve medical outcome 
following MI by treating depression. However, the intervention did not increase 
event-free survival in the primary analysis [3]. Chapter 7 was based on a secondary 
analysis of a study to the effect of omega-3 augmentation of sertraline for the 
treatment of depression in patients with CHD. Although ECG patterns can be used 
to screen for OSAH [7], polysomnography is the gold standard for diagnosis of the 
disorder.  
Implications for clinical practice and future research 
Prognostic differences between symptom dimensions of distress  
The finding of a larger association of somatic depressive symptoms after ACS with 
mortality in chapter 5 is in concordance with other studies that found that somatic 
depressive symptoms and not cognitive depressive symptoms were associated with 
adverse outcomes in patients following acute MI [11-13]. In addition, somatic 
depressive symptoms were better predictors of adverse outcomes in patients with 
myocardial ischemia [14], heart failure [15], and stable CHD [16]. However, two 
studies in patients treated with CABG surgery found that cognitive depressive 
symptoms were predictive of cardiac mortality and somatic depressive symptoms 
were not [17,18]. Also, in a study using a structured diagnostic interview, both 
somatic and cognitive depressive symptoms were associated with adverse outcome 
following acute MI [19], suggesting that the association between depressive 
symptom dimensions and prognosis might depend on the type of depression 
assessment. More research is needed to evaluate the relationship between 
depressive symptom dimensions measured with questionnaires and diagnostic 
interviews and cardiac prognosis in different patient populations. Meanwhile, 
besides treating depression as a homogeneous disorder, researchers and clinicians 
should also pay specific attention to somatic depressive symptoms. Close 
monitoring of changes in somatic depressive symptoms might help to improve 
clinical care for depressed MI patients. If patients do not respond to antidepressant 
treatment with significantly improved somatic symptoms, additional treatments 




Although several studies have focused on differential associations between 
depressive symptoms and cardiac prognosis, this research is lacking for anxiety. To 
date, only one study assessed the association of somatic and cognitive symptoms of 
anxiety with risk of CHD [20]. This prospective cohort study showed that, while 
the association between somatic symptoms of anxiety and incident CHD did not 
remain significant after adjustment for sociodemographic characteristics, 
biobehavioral risk factor and symptoms of depression in men, somatic symptoms 
of anxiety were independently related with an increased risk of incident CHD 
events in women [20]. Future research should assess the potential differential 
impact of somatic and cognitive symptoms of anxiety in patients with CHD. 
Furthermore, future research should carefully assess the possible confounding role 
of cardiac disease severity in the relationship between somatic symptoms of 
distress and cardiovascular outcomes.  
Treatment of anxiety and depression in patients with CHD 
The first part of this thesis showed that the prevalence of anxiety is relatively high 
in the general population and even higher in patients with CHD. Further, anxiety 
appeared to be associated with an increased risk of incident CHD and adverse 
prognosis following MI. Anxiety can be treated effectively with CBT and 
medications, e.g. benzodiazepines and selective serotonin reuptake inhibitors [21]. 
Unfortunately, many patients do not receive adequate treatment [21]. Clinicians 
should be aware of the possible presence of anxiety in their patients and treat 
anxiety to lower distress, decreasing the chances on disability and impaired quality 
of life. Further, clinicians should be aware of the risk of anxiety associated with 
CHD. 
Randomized controlled trials focusing on the effects of antidepressant treatment on 
depression and cardiac outcomes have found effects on depressive symptoms, 
although only modest, and no effect on cardiac outcomes [3,22]. It has been 
hypothesized that depression in cardiac patients might require other (nonstandard) 
treatments. Depression treatments that also modify cardiac risk markers in patients 
with CHD might lead to better depression and medical outcomes [6]. For example, 
exercise therapy may offer considerable promise in patients with heart disease 
through a decrease in depressive symptoms and by simultaneously modifying 
mechanisms by which depression may be associated with increased risk [23]. 
Results of the first part of this thesis further indicate that treatment of distressed MI 
patients should not focus on depression exclusively. One of the reasons large 





intervention trials have failed to improve medical prognosis in depressed MI 
patients might be that related anxiety was not treated [24]. It seems advisable to 
focus on both anxiety and depression in intervention trials, since comorbidity rates 
of anxiety and depressive disorders are high [25]. In addition, depressive disorders 
and anxiety disorders, especially GAD, are closely associated [26,27]. Risk factors 
for anxiety and depressive disorders overlap and neuroticism might be a shared 
heritable risk factor [28]. Because of the similarities among depressive and anxiety 
disorders, it is proposed that in the upcoming Diagnostic and Statistical Manual of 
Mental Disorders (DSM-V) mood and anxiety disorders should be subsumed 
together in an overarching class of emotional disorders. This class can then be 
decomposed into three subclasses: the distress disorders (major depression, 
dysthymic disorder, GAD, posttraumatic stress disorder), the fear disorders (panic 
disorder, agoraphobia, social phobia, specific phobia) and the bipolar disorders 
(bipolar I, bipolar II, cyclothymia) [29]. In conclusion, there is a need for more 
behavioral medicine programs performing clinical outcomes research [30], in 
which various risk factors, including depression and anxiety, should be targeted. 
Although it has been suggested that anxiety might have a more influential role in 
electrical instability resulting in ventricular arrhythmias and sudden cardiac death 
[24,31,32], analogous physiological mediating mechanisms are often proposed for 
both anxiety and depression leading to CHD, including heart rate variability [33-35] 
inflammatory processes [36,37], increased platelet activity [38,39], and 
hypothalamus-pituitary-adrenal axis dysregulation [40-42]. Another mechanism 
that may explain the association between anxiety and depression and CHD is 
unhealthy behavior, such as less compliance, physical inactivity, an unhealthy diet, 
and smoking. Depression and anxiety are related to an unhealthy lifestyle in 
individuals at risk of cardiovascular disease [43] and are associated with lower 
adherence to various risk-reducing recommendations in patients following an acute 
cardiac event [44,45]. To date, almost no research has been conducted assessing 
symptom dimensions of distress in relation to potential mediating mechanisms. 
However, one study found that in patients with stable CHD, somatic depressive 
symptoms were associated with lower heart rate variability, while cognitive 
depressive symptoms were not [35]. Further, it has been hypothesized that 
inflammation might be more strongly related to somatic, as opposed to affective, 
depressive symptoms [46]. Future research should focus on the possibility that 




physiological or behavioral mechanisms, rather than with depression in general 
[37].   
Behavioral and physiological pathways through which distress influences CHD 
progression are probably intertwined. A recent report from the Heart and Soul 
study found that the association between depression and subsequent inflammation 
was eliminated after adjustment for smoking, higher body mass index and physical 
inactivity [47]. Also in the Heart and Soul study, lifestyle factors accounted for 
almost 50% of the association between depression and new cardiac events in stable 
CHD patients, mainly through lack of physical activity, while physiological factors 
were only minimally associated with prognosis [48]. Behavioral mechanisms might 
thus be more strongly related to adverse cardiac outcomes as compared with 
biological mechanisms. Intervening on lifestyle factors might therefore improve 
cardiac prognosis of distressed CHD patients.  
Non-response to antidepressant treatment and the association with adverse cardiac 
prognosis 
Secondary analyses from several clinical trials in patients with CHD suggest that 
depression that does not respond to treatment is associated with a particularly high 
risk of adverse cardiac outcomes [4-6]. Since residual symptoms after depression 
treatment are often somatic [49,50], somatic depressive symptoms might reflect 
persistent or chronic depression and this might explain the differential associations 
found for somatic and cognitive depressive symptoms with impaired prognosis in 
patients with CHD. Further, comorbid anxiety disorder is a powerful predictor of 
non-response to antidepressant treatment [51], stressing the importance of detecting 
and treating comorbid anxiety in depressed patients. Notably, the prevalence of 
comorbid anxiety disorders is higher among depressed patients exhibiting somatic 
depressive symptoms as compared to other depressed patients [52], indicating the 
importance of studying the relationship between somatic depressive symptoms and 
anxiety and the effect of interventions aimed to diminish distress.  
The association between treatment resistant depression and adverse cardiac 
outcomes might also be partly explained by undiagnosed OSAH, since OSAH 
increases the risk of CHD [53] and is associated with a poor response to 
antidepressant medication (i.e. sertraline). In addition, also CBT appears to be less 
efficacious in post-MI patients with comorbid OSAH [54]. Future research should 
determine the contribution of OSA to the increased risk of adverse cardiac 





outcomes associated with treatment resistant depression. Also, comorbid OSAH 
should be identified and treated in patients with CHD, potentially leading to a 
better cardiac prognosis. Additionally, studies are needed to identify better 
treatments for depression in the presence of OSAH, especially in patients with 
CHD.  
Concluding remarks 
This thesis illustrates that, besides depression, anxiety is a psychological factor that 
plays a role in the relationship between psychological variables and CHD. Whether 
depression and anxiety are causal risk factors for CHD, or risk markers, has not yet 
been established. Although both are associated with adverse cardiac prognosis, to 
date no study has convincingly shown that treatment of anxiety and/or depression 
improves medical prognosis of patients with CHD. Also, effects of psychological 
interventions on psychological distress in patients with CHD are only modest. 
Future research examining the relationship between psychological factors and 
CHD should take into account differential associations between symptoms 
dimensions of distress and prognosis, the comorbidity between anxiety and 
depression, and factors that predict non-response to antidepressant treatment, in 
order to improve psychological status and potentially the medical prognosis of 
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Hart- en vaatziekten (HVZ) zijn één van de meest voorkomende oorzaken van 
morbiditeit en mortaliteit in geïndustrialiseerde landen [1,2]. In Nederland waren 
HVZ de oorzaak van ongeveer 30% van alle sterftegevallen in 2009 [3]. Coronaire 
hartziekten (CHZ) verwijzen naar een abnormaliteit in de coronaire arteriën, over 
het algemeen als resultaat van atherosclerose, waardoor minder bloed en zuurstof 
naar het hart kan worden getransporteerd. Blokkades in de coronaire arteriën 
kunnen leiden tot een acuut myocardinfarct (MI). Naast traditionele risicofactoren 
van CHZ heeft onderzoek aangetoond dat er een associatie is tussen 
psychologische factoren, zoals stress, en CHZ [4,5]. Angst- en 
stemmingsstoornissen zijn klinische uitingen van stress en kunnen accuraat worden 
gediagnosticeerd [6]. In vergelijking met de algemene volwassen bevolking is de 
prevalentie van angst- en stemmingsstoornissen met een factor van 1,5 tot 2 keer 
verhoogd in patiënten met CHZ. Geschat wordt dat het aantal hartpatiënten in 
Nederland dat lijdt aan een stemmingsstoornis tussen de 35.000 en 80.000 per jaar 
ligt. De prevalentie van angststoornissen wordt geschat tussen de 70.000 en 90.000 
per jaar [7].  
Doel van het proefschrift 
Het algemene doel van dit proefschrift was om de rol van angst en depressie in 
CHZ te onderzoeken. Het eerste deel van het proefschrift richtte zich op de relatie 
tussen angst en CHZ. Eerdere onderzoeken naar de effecten van angst op CHZ 
vonden wisselende resultaten. In sommige studies werd een relatie gevonden 
tussen angst en de ontwikkeling of progressie van CHZ [8-11], terwijl andere 
studies geen effect van angst op CHZ vonden [12,13]. Het specifieke doel van deel 
1 van het proefschrift was om nader te onderzoeken of angst invloed heeft op het 
ontwikkelen van CHZ in een, op baseline, gezonde populatie en of angst invloed 
heeft op morbiditeit en mortaliteit in patiënten met CHZ.  
In deel 2 van het proefschrift werd ingegaan op de relatie tussen depressie en CHZ. 
In vergelijking met angst is er naar het potentiële effect van depressie of CHZ veel 
meer onderzoek gedaan. Verschillende meta-analyses suggereren dat depressie een 
risicofactor is voor het ontwikkelen van CHZ in de algemene populatie en dat 
depressie is geassocieerd met een slechte medische prognose in patiënten met CHZ. 
Ondanks het aanzienlijk aantal uitgevoerde studies zijn er nog veel onopgeloste 




behandeling van depressie in patiënten met CHZ tot nu toe geen effect laten zien 
op de cardiovasculaire prognose. Daarnaast was het effect van de behandeling op 
depressieve symptomen matig [15,16]. Daarentegen heeft verder onderzoek van 
deze studies laten zien dat bepaalde subgroepen patiënten (bijvoorbeeld blanke 
mannen en patiënten behandeld met selectieve serotonine heropnameremmers) een 
gunstigere medische prognose hadden [17,18]. Secundaire analyses van deze 
studies hebben daarnaast laten zien dat patiënten die niet reageerden op de 
depressie behandeling een hoger risico hadden op cardiovasculaire morbiditeit en 
mortaliteit [19,20]. Depressie die niet reageert op behandeling lijkt dus gepaard te 
gaan met een extra verhoogd risico op een ongunstige cardiovasculaire prognose 
[21]. Verder hebben een aantal recente studies laten zien dat subdomeinen van 
depressie verschillend gerelateerd zijn aan cardiovasculaire uitkomstmaten. In MI 
patiënten bleken alleen somatische depressieve symptomen (zoals vermoeidheid en 
slaapproblemen) een voorspeller te zijn van cardiovasculaire morbiditeit en 
mortaliteit. Cognitieve depressieve symptomen (zoals schuldgevoelens en 
schaamte) waren niet gerelateerd aan prognose [22-24]. Echter, in studies in 
patiënten die een bypass operatie ondergingen werd gevonden dat cognitieve 
depressieve symptomen wel, maar somatisch depressieve symptomen niet, 
gerelateerd waren aan cardiovasculaire morbiditeit en mortaliteit [25,26].  
De voorgaande studies laten zien dat het geïndiceerd is om de relatie tussen 
depressieve symptomen en CHZ nader te bekijken. Teneinde depressieve 
symptomen en de prognose van hartpatiënten te verbeteren is het belangrijk om na 
te gaan welke subtypen van depressie belangrijkere voorspellers zijn van 
cardiovasculaire uitkomstmaten dan anderen en welke patiënten niet adequaat 























Voornaamste bevindingen van het proefschrift 
De relatie tussen angst en de ontwikkeling en progressie van CHZ 
Hoofdstuk 2 beschrijft de resultaten van een meta-analyse waarin de invloed van 
angst op het ontwikkelen van CHZ onderzocht werd in personen die bij aanvang 
van de studie geen hartziekte hadden. Deze studie bevatte 20 studies met een totaal 
aantal van 249.846 personen en liet zien dat angstige personen een 26% verhoogd 
risico hadden op het ontwikkelen van CHZ en een 48% verhoogd risico te 
overlijden aan CHZ. Deze relatie was onafhankelijk van demografische variabelen, 
biologische risicofactoren van CHZ en gedragsfactoren. De resultaten van deze 
meta-analyse suggereren dat angst een onafhankelijke risicofactor is voor CHZ en 
cardiovasculaire mortaliteit in de algemene bevolking. 
Hoofdstuk 3 beschrijft de resultaten van een tweede meta-analyse. Hierin werd de 
prognostische associatie tussen angst in MI patiënten en medische uitkomstmaten 
onderzocht. Deze meta-analyse bevatte 12 artikelen en 5.750 patiënten. De 
resultaten lieten zien dat angst na een MI consistent gerelateerd was aan algemene 
mortaliteit, cardiovasculaire mortaliteit en cardiovasculaire morbiditeit. Angstige 
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patiënten hadden een 36% verhoogd risico op een ongunstige prognose in 
ongecontroleerde analyses. Er is echter meer onderzoek nodig om te onderzoeken 
of deze associatie onafhankelijk is van andere psychologische en klinische 
variabelen.  
In Hoofdstuk 4 onderzochten we de relatie tussen gegeneraliseerde angststoornis 
(GAS) na MI en cardiovasculaire morbiditeit en mortaliteit over een follow-up van 
10 jaar. We analyseerden tevens of GAS een voorspeller was van een ongunstige 
prognose na controle voor depressieve stoornis. Patiënten in deze studie waren 
acute MI patiënten (n=438) die geïncludeerd waren voor de Depressie na Myocard 
Infarct (depreMI) studie [27]. MI patiënten met GAS hadden een bijna 2 keer 
verhoogd risico op cardiovasculaire morbiditeit en algemene mortaliteit en deze 
associatie was onafhankelijk van demografische en klinische variabelen en 
depressie.  
Samengevat laten de resultaten van deze studies zien dat angst is geassocieerd met 
een verhoogd risico op het ontwikkelen van CHZ en een ongunstige prognose van 
CHZ in MI patiënten. Deze associatie lijkt bovendien onafhankelijk te zijn van de 
invloed van traditionele cardiovasculaire risicofactoren en depressie. Deze studies 
zetten angst op de kaart als een potentiële risicofactor voor het ontwikkelen van 
CHZ in de algemene bevolking en cardiovasculaire morbiditeit en mortaliteit in 
hartpatiënten. De resultaten van deze studies duiden de noodzaak aan van verder 
onderzoek naar de relatie tussen angst en CHZ en de identificatie van de 
onderliggende processen.  
De relatie tussen dimensies van depressieve symptomen, reactie op behandeling, en 
CHZ  
Hoofdstuk 5 onderzocht de differentiële relaties tussen dimensies van depressieve 
symptomen en ziekte-ernst en mortaliteit in patiënten met een acuut coronair 
syndroom (ACS). Dit was een prospectieve studie die patiënten volgde die 
opgenomen waren met een MI of instabiele angina pectoris (n=913) in 12 
ziekenhuizen in Ontario, Canada [28]. Somatisch/affectieve depressieve 
symptomen waren gerelateerd aan Killip klasse bij aanvang van de studie. Verder 
waren somatisch/affectieve depressieve symptomen, en niet cognitief/affectieve 
depressieve symptomen, voorspellend voor mortaliteit op 12 maanden follow-up. 





In Hoofdstuk 6 werd een secundaire analyse uitgevoerd op 1254 MI patiënten met 
een depressieve stoornis uit de Enhancing Recovery in Coronary Heart Disease 
(ENRICHD) studie. ENRICHD is een gerandomiseerde gecontroleerde studie met 
als doel te onderzoeken of behandeling van depressie met cognitieve 
gedragstherapie (CGT), indien nodig aangevuld met antidepressiva, de medische 
prognose van MI patiënten kon verbeteren. In de primaire analyse had deze 
interventie geen effect op cardiovasculaire morbiditeit en mortaliteit [29]. In 
hoofdstuk 6 werd onderzocht of veranderingen in somatische en cognitieve 
depressieve symptomen voorspellend waren voor de prognose en of de resultaten 
verschilden tussen de behandel- en controlegroep. De patiënten in de 
interventiegroep hadden een grotere verbetering in hun cognitieve en somatische 
depressieve symptomen dan de patiënten in de controlegroep. Positieve 
veranderingen in somatische depressieve symptomen, maar niet in cognitieve 
depressieve symptomen, waren gerelateerd aan een lager risico op een nieuw MI of 
overlijden. Het effect van veranderingen in depressieve symptomen op prognose 
was afhankelijk van de behandeling. Na controle voor demografische en klinische 
variabelen hadden patiënten van wie de somatische depressieve symptomen 
verbeterden na CGT een betere prognose dan patiënten van wie de somatische 
depressieve symptomen niet verbeterden na CGT.  
Verschillende studies hebben uitgewezen dat therapieresistente depressie 
geassocieerd is met een extra verhoogd risico op cardiovasculaire morbiditeit en 
mortaliteit [19-21]. Obstructieve slaapapneu is een slaapgerelateerde 
ademhalingsstoornis die gekarakteriseerd wordt door herhaalde gedeeltelijke of 
complete afsluiting van de bovenste luchtwegen. Slaapapneu is een risicofactor 
voor CHZ [30] en geassocieerd met therapieresistente depressie in psychiatrische 
patiënten [31]. Het doel van hoofdstuk 7 was om te onderzoeken of obstructieve 
slaapapneu gerelateerd is aan reactie op antidepressiva in patiënten met CHZ. Deze 
vraag werd onderzocht in data van een gerandomiseerd dubbelblind onderzoek naar 
ophoging van sertraline met omega-3 voor depressie in patiënten met CHZ. De 
primaire resultaten van deze studie zijn elders gepubliceerd [32]. Na controle voor 
depressie score op baseline, interventie (omega-3 of placebo), body mass index, en 
inflammatie, bleek slaapapneu geassocieerd te zijn met een minder goede reactie 
op sertraline. Deze studie concludeert dat ongediagnosticeerde slaapapneu één van 
de oorzaken kan zijn van de relatie tussen therapieresistente depressie en 





Samengevat geven deze studies meer inzicht in de complexe relatie tussen 
depressie en CHZ. Ten eerste lijken somatische depressieve symptomen 
belangrijkere voorspellers te zijn van prognose in patiënten met ACS dan 
cognitieve depressieve symptomen. Verder vonden we dat verbeteringen in 
somatische depressieve symptomen na behandeling met CGT geassocieerd waren 
met een verbeterde cardiovasculaire prognose in depressieve MI patiënten. Ten 
slotte blijkt slaapapneu gerelateerd te zijn aan een verminderde reactie op sertraline, 
wat suggereert dat de associatie tussen therapieresistente depressie en 
cardiovasculaire morbiditeit en mortaliteit mogelijk gedeeltelijk verklaard kan 
worden door ongediagnosticeerde slaapapneu.  
Concluderende opmerkingen 
Dit proefschrift laat zien dat, naast depressie, angst een psychologische factor is die 
een rol speelt in de relatie tussen psychologisch factoren en CHZ. Of angst en 
depressie causale risicofactoren zijn van CHZ, of kenmerken van risicoverhoging, 
is nog onduidelijk. Ondanks dat beiden geassocieerd zijn met cardiovasculaire 
morbiditeit en mortaliteit hebben studies nog niet overtuigend aangetoond dat 
behandeling van angst en/of depressie de prognose van hartpatiënten verbetert. 
Ook zijn de effecten van psychologische interventies op angst en depressie matig. 
Verder onderzoek naar de relatie tussen psychologische factoren en CHZ dient 
rekening te houden met differentiële relaties tussen symptoomdimensies van angst 
en depressie en cardiovasculaire prognose. Ook factoren die een verminderde 
reactie op antidepressiva voorspellen dienen te worden onderzocht. Onderzoek in 
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